



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 15/12, 5/10, 1/21, C07K 14/47, 16/18, C12Q 1/68, A61K 38/17</p>	A2	<p>(11) International Publication Number: <b>WO 99/64593</b></p> <p>(43) International Publication Date: 16 December 1999 (16.12.99)</p>
<p>(21) International Application Number: PCT/US99/12906</p> <p>(22) International Filing Date: 8 June 1999 (08.06.99)</p> <p>(30) Priority Data: 60/088,695 8 June 1998 (08.06.98) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/088,695 (CIP) Filed on 8 June 1998 (08.06.98)</p> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah,</p>	<p>R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: CELL CYCLE REGULATION PROTEINS</p>		
<p>(57) Abstract</p> <p>The invention provides a human cell cycle regulation proteins (CECRP) and polynucleotides which identify and encode CECRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of CECRP.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CELL CYCLE REGULATION PROTEINS

### TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of cell cycle  
5 regulation proteins and to the use of these sequences in the diagnosis, treatment, and  
prevention of cell proliferative and immune disorders.

### BACKGROUND OF THE INVENTION

Cell division is the fundamental process by which all living things grow and  
10 reproduce. In unicellular organisms such as yeast and bacteria, each cell division doubles  
the number of organisms, while in multicellular species many rounds of cell division are  
required to replace cells lost by wear or by programmed cell death, and for cell  
differentiation to produce a new tissue or organ. Details of the cell division cycle may  
vary, but the basic process consists of three principle events. The first event, interphase,  
15 involves preparations for cell division, replication of the DNA, and production of essential  
proteins. In the second event, mitosis, the nuclear material is divided and separates to  
opposite sides of the cell. The final event, cytokinesis, is division and fission of the cell  
cytoplasm. The sequence and timing of cell cycle transitions is under the control of the  
cell cycle regulation system which controls the process by positive or negative regulatory  
20 circuits at various check points.

Regulated progression of the cell cycle depends on the integration of growth  
control pathways with the basic cell cycle machinery. Cell cycle regulators have been  
identified by selecting for human and yeast cDNAs that block or activate cell cycle arrest  
signals in the yeast mating pheromone pathway when they are over expressed. Known  
25 regulators include human CPR (cell cycle progression restoration) genes, such as CPR8  
and CPR2, and yeast CDC (cell division control) genes, including CDC91, that block the  
arrest signals. The CPR genes express a variety of proteins including cyclins, tumor  
suppressor binding proteins, chaperones, transcription factors, translation factors, and  
RNA-binding proteins (Edwards, M. C. et al.(1997) Genetics 147:1063-1076.)

30 Several cell cycle transitions, including the entry and exit of a cell from mitosis,  
are dependent upon the activation and inhibition of cyclin-dependent kinases (Cdks). The

Cdks are composed of a kinase subunit, Cdk, and an activating subunit, cyclin, in a complex that is subject to many levels of regulation. There appears to be a single Cdk in *S. cerevisiae* and *S. pombe* whereas mammals have a variety of specialized Cdks. Cyclins act by binding to and activating cyclin-dependent protein kinases which then

5 phosphorylate and activate selected proteins involved in the mitotic process. The Cdk-cyclin complex is both positively and negatively regulated by phosphorylation, and by targeted degradation involving molecules such as CDC4 and CDC53. In addition, Cdks are further regulated by binding to inhibitors and other proteins such as Suc1 that modify their specificity or accessibility to regulators. (Patra, D., and Dunphy, W. G.

10 (1996) Genes Dev. 10:1503-1515; and Mathias, N. et al. (1996) Mol. Cell Biol. 16: 6634-6643.)

Modulation of mRNA processing plays an important role during the cell cycle as many transcripts are differentially regulated in distinct cell types and tissues. mRNA processing includes differential, or alternate splicing of exons, which allows the

15 expression of functionally distinct proteins from similar mRNAs. Both constitutive and alternative splicing occurs on spliceosomes, which are complex particles composed of small nuclear ribonucleoproteins (snRNPs) and non-snRNP proteins. The SR (serine- and arginine-rich) family of non-snRNP splicing factors are required at early stages of spliceosome assembly, have distinct but overlapping specificities for different

20 pre-mRNAs, and can alter splice site choice. Several of the mammalian SR proteins including HRS, ASF/SF2, and SC-35, have been characterized. The sequence of HRS is related to the human ASF/SF2 protein and the *Drosophila* B52/SRp55 protein. The latter has been shown to function *in vitro* to regulate 5-prime splice site selection. (Diamond, R. H. et al. (1993) J. Biol. Chem. 268:15185-15192.)

25 Cell cycle progression also requires coordinated expression of other proteins. Blimp-1 regulatory factor appears during the differentiation of B lymphocytes into immunoglobulin secretory cells. Blimp-1 contains Kruppel-type zinc finger motifs and proline-rich and acidic regions similar to those of known transcription factors. Stable or transient transfection of Blimp-1 into B cell lymphoma lines leads to the expression of

30 many of the phenotypic changes associated with B cell differentiation into an early plasma cell stage, including induction of J chain message and immunoglobulin secretion,

up-regulation of syndecan-1, and increased cell size and granularity. Inhibin, a member of the transforming growth factor beta-like family has been shown to modulate cell differentiation and proliferation by antagonizing the DNA synthesis activity of activin. (Turner, C.A. et al. (1994) Cell (1994) 77:297-306; and Matzuk, M. M. et al. (1994) Proc. Nat. Acad. Sci. 91:8817-8821.)

Progression through the cell cycle and consequently, cell proliferation, is governed by the complex interactions of protein complexes composed of cyclins, cyclin-dependent protein kinases, cell growth factors, binding of inhibitory polypeptides, and associated proteins. Cancers and immune disorders are characterized by uncoordinated cell proliferation. Certain cell proliferation disorders can be identified by changes in the protein complexes that normally control progression through the cell cycle. A primary treatment strategy involves reestablishing control over cell cycle progression by manipulation of the proteins involved in cell cycle regulation. (Nigg, E.A. (1995) BioEssays 17:471-480.)

The discovery of new cell cycle regulation proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, and prevention of cell proliferative and immune disorders.

20

### SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, cell cycle regulation proteins, referred to collectively as "CECRP" and individually as "CECRP-1", "CECRP-2", "CECRP-3", "CECRP-4", and "CECRP-5". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, (SEQ ID NO:1 through 5) and fragments thereof.

The invention further provides a substantially purified variant having at least 90% amino acid identity to the amino acid sequences of SEQ ID NO:1 through 5, and fragments thereof. The invention also provides an isolated and purified polynucleotide

encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 70% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting SEQ ID NO:1 through 5, and fragments thereof, as well as an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, (SEQ ID NO:6 through 10), and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:6 through 10, and fragments thereof as well as an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:6 through 10, and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide

encoding the polypeptide under conditions suitable for the expression of the polypeptide;  
and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group  
5 consisting of SEQ ID NO:1 through 5, and fragments thereof in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof, as well as a purified agonist and a purified antagonist to  
10 the polypeptide.

The invention also provides a method for treating or preventing a cell proliferative disorder, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID  
15 NO:1 through 5, and fragments thereof in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a cell proliferative disorder, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of the polypeptide having an amino acid sequence  
20 selected from the group consisting of SEQ ID NO:1 through 5 and fragments thereof.

The invention also provides a method for treating or preventing an immune disorder, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID  
25 NO:1 through 5, and fragments thereof in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing an immune disorder, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of the polypeptide having an amino acid sequence  
30 selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof.

The invention also provides a method for detecting a polynucleotide encoding the

polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof in a biological sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence encoding the polypeptide comprising the amino acid sequence  
5 selected from the group consisting of SEQ ID NO:1 through 5, and fragments thereof to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding the polypeptide in the biological sample. In one aspect, the nucleic acids of the biological  
10 sample are amplified by the polymerase chain reaction prior to the hybridizing step.

### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is  
15 understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

20 It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

25 Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned  
30 herein are cited for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications and which might be used in

connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

## DEFINITIONS

5 "CECRP," as used herein, refers to the amino acid sequences of substantially purified CECRP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist," as used herein, refers to a molecule which, when bound to  
10 CECRP, increases or prolongs the duration of the effect of CECRP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of CECRP.

An "allelic variant," as this term is used herein, is an alternative form of the gene encoding CECRP. Allelic variants may result from at least one mutation in the nucleic  
15 acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the  
20 others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding CECRP, as described herein, include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as CECRP or a polypeptide with at least one functional characteristic of CECRP. Included within this definition are polymorphisms  
25 which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding CECRP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding CECRP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change  
30 and result in a functionally equivalent CECRP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity,

hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of CECRP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having  
5 similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence," as used herein, refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic  
10 fragments," or "antigenic fragments" refer to fragments of CECRP which are preferably about 5 to about 15 amino acids in length, most preferably 14 amino acids, and which retain some biological activity or immunological activity of CECRP. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino  
15 acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification," as used herein, relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art. (See, e.g., Dieffenbach, C.W. and G.S.  
20 Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, pp.1-5.)

The term "antagonist," as it is used herein, refers to a molecule which, when bound to CECRP, decreases the amount or the duration of the effect of the biological or immunological activity of CECRP. Antagonists may include proteins, nucleic acids,  
25 carbohydrates, antibodies, or any other molecules which decrease the effect of CECRP.

As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind CECRP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the  
30 immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized

chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

5           The term "antigenic determinant," as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic  
10 determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

          The term "antisense," as used herein, refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis  
15 or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

          As used herein, the term "biologically active," refers to a protein having structural,  
20 regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic CECRP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

          The terms "complementary" or "complementarity," as used herein, refer to the  
25 natural binding of polynucleotides under permissive salt and temperature conditions by base pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of  
30 complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular

importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence," as these terms are used herein, refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation, an aqueous solution, or a sterile composition. Compositions comprising polynucleotide sequences encoding CECRP or fragments of CECRP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts, e.g., NaCl, detergents, e.g., sodium dodecyl sulfate (SDS), and other components, e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.

"Consensus sequence," as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW™ Fragment Assembly system (GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence.

As used herein, the term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding CECRP, by Northern analysis is indicative of the presence of nucleic acids encoding CECRP in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding CECRP.

A "deletion," as the term is used herein, refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative," as used herein, refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at

least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

5           The term "similarity," as used herein, refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary  
10 sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency  
15 are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or  
20 probe will not hybridize to the second non-complementary target sequence.

          The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MegAlign™ program (DNASTAR, Inc., Madison WI). The MegAlign™ program can create alignments  
25 between two or more sequences according to different methods, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) *Gene* 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of  
30 sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and

sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 5 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

“Human artificial chromosomes” (HACs), as described herein, are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance. (See, e.g., Harrington, J.J. et al. (1997) *Nat Genet.* 15:345-355.) 10

The term "humanized antibody," as used herein, refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

15 “Hybridization,” as the term is used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

As used herein, the term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or 20  $R_0t$  analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words “insertion” or “addition,” as used herein, refer to changes in an amino 25 acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

“Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other 30 signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray," as used herein, refers to an arrangement of distinct

polynucleotides arrayed on a substrate, e.g., paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The terms "element" or "array element" as used herein in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

5 The term "modulate," as it appears herein, refers to a change in the activity of CECRP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of CECRP.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a  
10 nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, comprise a region of unique polynucleotide  
15 sequence that specifically identifies a polynucleotide of SEQ ID NO:6-10, for example, as distinct from any other sequence in the same genome. For example, a fragment of a polynucleotide of SEQ ID NO:6-10 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:6-10 from related polynucleotide sequences. A fragment of a polynucleotide of SEQ ID NO:6-10 is at least  
20 about 15-20 nucleotides in length. The precise length of the fragment of polynucleotide of SEQ ID NO:6-10 and the region of a polynucleotide of SEQ ID NO:6-10 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. Alternatively, a fragment when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or  
25 structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" or "operably linked," as used herein, refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be  
30 contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to

operator sequences that control expression of the polypeptide.

The term "oligonucleotide," as used herein, refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in  
5 a hybridization assay or microarray. As used herein, the term "oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA), as used herein, refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in  
10 length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell. (See, e.g., Nielsen, P.E. et al. (1993) *Anticancer Drug Des.* 8:53-63.)

15 The term "sample," as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acids encoding CECRP, or fragments thereof, or CECRP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a solid support; a tissue; a tissue print; etc.

20 As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope  
25 A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

As used herein, the term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent (e.g.,  
30 formamide), temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the

concentration of formamide, or raising the hybridization temperature.

The term “substantially purified,” as used herein, refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably  
5 about 90% free from other components with which they are naturally associated.

A “substitution,” as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

“Transformation,” as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or  
10 artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term  
15 “transformed” cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A “variant” of CECRP, as used herein, refers to an amino acid sequence that is  
20 altered by one or more amino acids. The variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have “nonconservative” changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in  
25 determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE™ software.

The term “variant,” when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to CECRP. This definition may also  
30 include, for example, “allelic” (as defined above), “splice,” “species,” or “polymorphic” variants. A splice variant may have significant identity to a reference molecule, but will

generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will

5 have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state,

10 or a propensity for a disease state.

### THE INVENTION

The invention is based on the discovery of new cell cycle regulation proteins (CECRP), the polynucleotides encoding CECRP, and the use of these compositions for the

15 diagnosis, treatment, or prevention of diseases associated with cell proliferation and immune disorders.

In Table 1, columns 1 and 2 show the sequence identifiers for each of the amino acid and nucleic acid sequence, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each CECRP were first identified, and column 4,

20 the cDNA library of this clone. Column 5 is entitled fragments, and shows the Incyte clones (and libraries) and shotgun sequences useful as fragments, for example, in hybridization technologies, and which are part of the consensus nucleotide sequence of each CECRP. The columns of Table 2 show various properties of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino

25 acid residues; column 3, potential phosphorylation sites; column 4, potential glycosylation sites; column 5, identifying sequences and/or structural motifs; and column 6, analytical methods used to identify the protein through sequence homologies and protein motifs.

The columns of Table 3 show the tissue expression of each nucleic acid sequence by Northern analysis, diseases or disorders associated with this tissue expression, and the

30 vector into which each cDNA was cloned.

The invention also encompasses CECRP variants. A preferred CECRP variant is

one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the CECRP amino acid sequence, and which contains at least one functional or structural characteristic of CECRP.

The invention also encompasses polynucleotides which encode CECRP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising the sequence selected from the group consisting of SEQ ID NO:6 through 10.

The invention also encompasses a variant of a polynucleotide sequence encoding CECRP. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding CECRP. A particular aspect of the invention encompasses a variant of a nucleic acid sequence selected from the group consisting of SEQ ID NO:6 through 10 which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:6 through SEQ ID NO:10. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of CECRP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding CECRP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring CECRP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode CECRP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring CECRP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding CECRP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a

particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding CECRP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable  
5 properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode CECRP and CECRP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available  
10 expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding CECRP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown  
15 in SEQ ID NO:6 through 10, or a fragments thereof, under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.)

Methods for DNA sequencing and analysis are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The  
20 methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE® (Amersham Pharmacia Biotech, Piscataway NJ), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System (Life Technologies, Gaithersburg MD). Preferably, sequence  
25 preparation is automated with machines such as the ABI Catalyst 800 (Perkin Elmer) or a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with thermal cyclers (for PCR). Sequencing is then carried out using either ABI 373 or 377 DNA sequencers (Perkin Elmer) or the MEGABASE capillary electrophoresis (Molecular Dynamics), and the sequences are analyzed using tools (computer programs and algorithms) which are  
30 well known in the art. (Ausubel (1997, unit 7.7); Meyers, R.A. (1995; Molecular Biology and Biotechnology, Wiley VCH, Inc, New York NY, p 856-853).

The nucleic acid sequences encoding CECRP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers  
5 to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988)  
10 Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before  
15 performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-306). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods,  
20 primers may be designed using commercially available software, such as OLIGO™ 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have  
25 been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used  
30 to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic

separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., Genotyper™ and Sequence Navigator™, Perkin Elmer), and the entire process from  
5 loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode CECRP may be cloned in recombinant DNA molecules that direct  
10 expression of CECRP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express CECRP.

The nucleotide sequences of the present invention can be engineered using  
15 methods generally known in the art in order to alter CECRP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis  
20 may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding CECRP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res.  
25 Symp. Ser. 225-232.) Alternatively, CECRP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin Elmer). Additionally, the amino acid sequence of CECRP, or any part  
30 thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and  
5 Molecular Properties, WH Freeman and Co., New York, NY.)

In order to express a biologically active CECRP, the nucleotide sequences encoding CECRP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements  
10 include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding CECRP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding CECRP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the  
15 Kozak sequence. In cases where sequences encoding CECRP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be  
20 provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct  
25 expression vectors containing sequences encoding CECRP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, ch. 4, 8, and 16-17; and Ausubel, F.M. et al. (1995, and periodic  
30 supplements) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding CECRP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems  
5 infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected  
10 depending upon the use intended for polynucleotide sequences encoding CECRP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding CECRP can be achieved using a multifunctional *E. coli* vector such as Bluescript® (Stratagene) or pSport1™ plasmid (GIBCO BRL). Ligation of sequences encoding CECRP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a  
15 colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of CECRP are needed, e.g. for the  
20 production of antibodies, vectors which direct high level expression of CECRP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of CECRP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol  
25 oxidase, and PGH, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, *supra*; and Grant et al. (1987) *Methods Enzymol.* 153:516-54; Scorer, C. A. et al. (1994) *Bio/Technology* 12:181-184.)

30 Plant systems may also be used for expression of CECRP. Transcription of sequences encoding CECRP may be driven viral promoters, e.g., the 35S and 19S

promoters of CaMV used alone or in combination with the omega leader sequence from TMV. (Takamatsu, N. (1987) EMBO J. 6:307-311.) Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding CECRP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses CECRP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

For long term production of recombinant proteins in mammalian systems, stable expression of CECRP in cell lines is preferred. For example, sequences encoding CECRP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; and Lowy, I. et al. (1980) Cell 22:817-823.)

5 Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al (1981) J. Mol.

10 Biol. 150:1-14; and Murry, supra.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP) (Clontech, Palo Alto, CA),  $\beta$  glucuronidase and its substrate  $\beta$ -D-glucuronoside, or luciferase and its substrate luciferin

15 may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed.

20 For example, if the sequence encoding CECRP is inserted within a marker gene sequence, transformed cells containing sequences encoding CECRP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding CECRP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the

25 tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding CECRP and that express CECRP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques

30 which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of CECRP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, 5 monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on CECRP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN, Section IV; Coligan, J. E. et al. (1997 and periodic supplements) Current Protocols in Immunology, 10 Greene Pub. Associates and Wiley-Interscience, New York, NY; and Maddox, D.E. et al. (1983) *J. Exp. Med.* 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to 15 polynucleotides encoding CECRP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding CECRP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase 20 such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Pharmacia & Upjohn (Kalamazoo, MI), Promega (Madison, WI), and U.S. Biochemical Corp. (Cleveland, OH). Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as 25 substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding CECRP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood 30 by those of skill in the art, expression vectors containing polynucleotides which encode CECRP may be designed to contain signal sequences which direct secretion of CECRP

through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding CECRP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric CECRP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of CECRP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the CECRP encoding sequence and the heterologous protein sequence, so that CECRP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel, F. M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, ch 10. A variety of commercially available

kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled CECRP may be achieved in vitro using the TNT™ rabbit reticulocyte lysate or wheat germ extract systems (Promega, Madison, WI). These systems couple transcription and translation of protein-  
5 coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably <sup>35</sup>S-methionine.

Fragments of CECRP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra  
10 pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of CECRP may be synthesized separately and then combined to produce the full length molecule.

## 15 THERAPEUTICS

Chemical and structural homology exists between CECRP and cell cycle regulation proteins. In addition the expression of CECRP is closely associated with cell proliferation. Therefore, in cancers or immune disorders where CECRP is an activator, or enhancer, and is promoting cell proliferation, it is desirable to decrease the expression of  
20 CECRP. In cancers or immune disorders where CECRP is an inhibitor or suppressor of cellular processes that modulate cell proliferation it is desirable to provide the protein or to increase the expression of CECRP.

In one embodiment, where CECRP is an inhibitor of cell proliferation, CECRP or a fragment or derivative thereof may be administered to a subject to treat or prevent a cell  
25 proliferation disorder. Such a disorder may include, but is not limited to, actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular,  
30 cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas,

parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a pharmaceutical composition comprising purified CECRP may be used to treat or prevent a cell proliferative disorder including, but not limited to, those listed above.

In another embodiment, an agonist which is specific for CECRP may be administered to a subject to treat or prevent a cell proliferative disorder including, but not limited to, those cancers listed above.

In another further embodiment, a vector capable of expressing CECRP, or a fragment or a derivative thereof, may be administered to a subject to treat or prevent a cell proliferative disorder including, but not limited to, those listed above.

In a further embodiment where CECRP is an inhibitor of cell proliferation, CECRP or a fragment or derivative thereof may be administered to a subject to treat or prevent an immune disorder. Such a disorder may include, but is not limited to, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

In another embodiment, a pharmaceutical composition comprising purified CECRP may be used to treat or prevent an immune disorder including, but not limited to, those listed above.

In another embodiment, an agonist which is specific for CECRP may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those listed above.

In another further embodiment, a vector capable of expressing CECRP, or a  
5 fragment or a derivative thereof, may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those listed above.

In yet another embodiment, where CECRP is a promoter of cell proliferation, antagonists which decrease the expression or activity of CECRP may be administered to a subject to treat or prevent a cell proliferation disorder including, but not limited to, those  
10 listed above. In one aspect, antibodies which specifically bind CECRP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express CECRP.

In another embodiment, a vector expressing the complement of the polynucleotide encoding CECRP may be administered to a subject to treat or prevent a cell proliferation  
15 disorder including, but not limited to, those listed above.

In yet another embodiment, where CECRP is a promoter of cell proliferation, antagonists which decrease the expression or activity of CECRP may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those listed  
above.

In another embodiment, a vector expressing the complement of the polynucleotide  
20 encoding CECRP may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those listed above.

In one further embodiment, CECRP or a fragment or derivative thereof may be added to cells to stimulate cell proliferation. In particular, CECRP may be added to a cell  
25 in culture or cells in vivo using delivery mechanisms such as liposomes, viral based vectors, or electroinjection for the purpose of promoting cell proliferation and tissue or organ regeneration. Specifically, CECRP may be added to a cell, cell line, tissue or organ culture in vitro or ex vivo to stimulate cell proliferation for use in heterologous or autologous transplantation. In some cases, the cell will have been preselected for its  
30 ability to fight an infection or a cancer or to correct a genetic defect in a disease such as sickle cell anemia,  $\beta$  thalassemia, cystic fibrosis, or Huntington's chorea.

In another embodiment, an agonist which is specific for CECRP may be administered to a cell to stimulate cell proliferation, as described above.

In another embodiment, a vector capable of expressing CECRP, or a fragment or a derivative thereof, may be administered to a cell to stimulate cell proliferation, as  
5 described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to  
10 conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of CECRP may be produced using methods which are generally  
15 known in the art. In particular, purified CECRP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind CECRP. Antibodies to CECRP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression  
20 library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with CECRP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species,  
25 various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

30 It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to CECRP have an amino acid sequence consisting of at least about 5 amino

acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of CECRP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to CECRP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce CECRP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; and Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for CECRP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression

libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the  
5 desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between CECRP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering CECRP  
10 epitopes is preferred, but a competitive binding assay may also be employed. (Maddox, supra.)

In another embodiment of the invention, the polynucleotides encoding CECRP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding CECRP may be used in situations in  
15 which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding CECRP. Thus, complementary molecules or fragments may be used to modulate CECRP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various  
20 locations along the coding or control regions of sequences encoding CECRP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid  
25 sequences complementary to the polynucleotides encoding CECRP. (See, e.g., Sambrook, supra; and Ausubel, supra.)

Genes encoding CECRP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding CECRP. Such constructs may be used to introduce untranslatable sense or  
30 antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous

nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by  
5 designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding CECRP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix  
base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the  
10 ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY, pp. 163-177.) A complementary sequence or antisense molecule may also be  
15 designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by  
20 endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding CECRP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the  
25 following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides  
30 using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be

prepared by any method known in the art for the synthesis of nucleic acid molecules.

These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding CECRP. Such DNA

5 sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life.

10 Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as

15 acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous

20 transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses,

25 rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of CECRP, antibodies to CECRP, and mimetics, agonists,

30 antagonists, or inhibitors of CECRP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be

administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by  
5 any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries  
10 which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using  
15 pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active  
20 compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose,  
25 hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as  
30 concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer

solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules  
5 made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with  
10 or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such  
15 as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain  
20 suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

25 The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with  
30 many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic

solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

5 After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of CECRP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions  
10 wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats,  
15 rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example CECRP or fragments thereof, antibodies of CECRP, and agonists, antagonists or  
20 inhibitors of CECRP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of therapeutic to toxic effects is the therapeutic index, and it can  
25 be expressed as the  $ED_{50}/LD_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the  
30 dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related

to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, 5 drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to 10 particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

15

## DIAGNOSTICS

In another embodiment, antibodies which specifically bind CECRP may be used for the diagnosis of disorders characterized by expression of CECRP, or in assays to monitor patients being treated with CECRP or agonists, antagonists, or inhibitors of 20 CECRP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for CECRP include methods which utilize the antibody and a label to detect CECRP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of 25 reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring CECRP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of CECRP expression. Normal or standard values for CECRP expression are established by 30 combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to CECRP under conditions suitable for complex formation. The

amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of CECRP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

5 In another embodiment of the invention, the polynucleotides encoding CECRP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of CECRP may be correlated with disease. The diagnostic assay may be  
10 used to determine absence, presence, and excess expression of CECRP, and to monitor regulation of CECRP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CECRP or closely related molecules may be used to identify nucleic acid sequences which encode CECRP.  
15 The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding CECRP, allelic variants, or related sequences.

20 Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the CECRP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequences of SEQ ID NO:6 through SEQ ID NO:10 or from genomic sequences including promoters, enhancers, and introns of the CECRP gene.

25 Means for producing specific hybridization probes for DNAs encoding CECRP include the cloning of polynucleotide sequences encoding CECRP or CECRP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides.  
30 Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as <sup>32</sup>P or <sup>35</sup>S, or by enzymatic labels, such as alkaline phosphatase

coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding CECRP may be used for the diagnosis of a disorder associated with expression of CECRP. Examples of such a disorder include, but are not limited to, actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma. The polynucleotide sequences encoding CECRP may be used in Southern or Northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patients to detect altered CECRP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding CECRP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding CECRP may be labeled by standard methods and

added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the  
5 presence of altered levels of nucleotide sequences encoding CECRP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with  
10 expression of CECRP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding CECRP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects  
15 with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated,  
20 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in  
25 biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

30 Additional diagnostic uses for oligonucleotides designed from the sequences encoding CECRP may involve the use of PCR. These oligomers may be chemically

synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding CECRP, or a fragment of a polynucleotide complementary to the polynucleotide encoding CECRP, and will be employed under optimized conditions for identification of a specific gene or condition.

- 5 Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of CECRP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J.

- 10 Immunol. Methods 159:235-244; and Duplaa, C. et al. (1993) Anal. Biochem. 229-236.)

The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

- In further embodiments, oligonucleotides or longer fragments derived from any of  
15 the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic  
20 agents.

- Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al.  
25 (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

- In another embodiment of the invention, nucleic acid sequences encoding CECRP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a  
30 specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial

chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical  
5 chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, R.A. (ed.) Molecular Biology and Biotechnology, VCH Publishers New York, NY, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding CECRP on a physical chromosomal map and a specific  
10 disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used  
15 for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery  
20 techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due  
25 to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, CECRP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located  
30 intracellularly. The formation of binding complexes between CECRP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some  
5 other surface. The test compounds are reacted with CECRP, or fragments thereof, and washed. Bound CECRP is then detected by methods well known in the art. Purified CECRP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

10 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding CECRP specifically compete with a test compound for binding CECRP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with CECRP.

In additional embodiments, the nucleotide sequences which encode CECRP may  
15 be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the  
20 preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications, mentioned above and  
below, in particular U.S. Ser. No. 60/088,695, are hereby expressly incorporated by  
25 reference.

## EXAMPLES

### I. Construction of cDNA Libraries

RNA was purchased from Clontech (Palo Alto, CA) or isolated at Incyte from  
30 tissues described in Table 4. The tissue was homogenized and lysed in guanidinium isothiocyanate, and the lysate was centrifuged over a CsCl cushion. Alternatively, the

tissue was homogenized and lysed in phenol or a suitable mixture of denaturants such as TRIzol reagent (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate, and the lysate was extracted with chloroform (1:5 v/v). RNA was precipitated from lysates with either isopropanol or sodium acetate and ethanol.

5 Alternatively, RNA was purified from lysates by preparative agarose gel electrophoresis and recovered from Whatman P81 paper (Whatman, Lexington, MA). Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity, and RNA was maintained in RNase-free solutions. In some cases, RNA was treated with DNase. For most libraries, poly(A<sup>+</sup>) RNA was isolated using oligo d(T)-coupled paramagnetic  
10 particles (Promega, Madison, WI), Oligotex resin, or the Oligotex kit (QIAGEN Inc, Chatsworth, CA). Alternatively, RNA was isolated directly from tissue lysates using the RNA Isolation kit (Stratagene) or the Ambion PolyA Quick kit (Ambion, Austin, TX).

RNA was used for cDNA synthesis and construction of the cDNA libraries according to procedures recommended in the UNIZAP vector (Stratagene, La Jolla, CA)  
15 or SuperScript plasmid system (Life Technologies, Inc), both of which are based on methods well known in the art (Ausubel, 1997, units 5.1-6.6). Alternatively, cDNA libraries were constructed by Stratagene using RNA provided by Incyte. Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and cDNA was digested with an  
20 appropriate restriction enzyme(s). For most libraries, cDNA was size-selected (300-1000 bp) using Sephacryl S1000 or Sepharose CL2B or CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., pBluescript (Stratagene), pSPORT 1 (Life Technologies), pINCY (Incyte  
25 Pharmaceuticals Inc, Palo Alto, CA). pINCY was amplified in JM109 cells and purified using the QiaQuick column (QIAGEN Inc). Recombinant plasmids were transformed into competent *E. coli* cells, e.g., XL1-Blue, XL1-BlueMRF, or SOLR (Stratagene) or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B (Life Technologies).

## 30 II. Isolation of cDNA Clones

Plasmids were recovered from host cells by *in vivo* excision (UniZAP vector

system, Stratagene) or by cell lysis. Plasmids were purified using the MAGIC  
MINIPREPS DNA purification system (Promega, Madison, WI); Miniprep kit (Advanced  
Genetic Technologies Corporation, Gaithersburg, MD); QIAwell-8 Plasmid, QIAwell  
PLUS DNA, or QIAwell ULTRA DNA purification systems; or REAL Prep 96 plasmid  
5 kit (QIAGEN Inc) using the recommended protocol. Following precipitation, plasmids  
were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at  
4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link  
PCR (Rao, V.B. (1994) Anal. Biochem. 216:1-14) in a high-throughput format. Host cell  
10 lysis and thermal cycling steps were carried out in a single reaction mixture. Samples  
were processed and stored in 384-well plates (Genetix Ltd, Christchurch UK) and  
concentration of amplified plasmid DNA was quantified fluorometrically using Pico Green  
Dye (Molecular Probes, Eugene OR) and a Fluoroscan II fluorescence scanner  
(Labsystems Oy, Helsinki, Finland).

15

### III. Sequencing and Analysis

The cDNAs were prepared for sequencing using either an ABI Catalyst 800  
(Perkin Elmer) or a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with  
Peltier Thermal Cyclers (PTC200; MJ Research, Watertown MA). The cDNAs were  
20 sequenced on the ABI 373 or 377 DNA Sequencing systems (Perkin Elmer) by the method  
of Sanger F and A.R. Coulson (1975; J. Mol. Biol. 94:441-448) using standard ABI  
protocols, base calling software, and kits. Alternatively, cDNAs were sequenced using  
solutions and dyes from Amersham Pharmacia Biotech. Reading frame was determined  
using standard methods (Ausubel, *supra*).

25 The cDNA sequences presented in Table 1 and the full length nucleotide and  
amino acid sequences disclosed in the Sequence Listing were queried against databases  
such as GenBank primate (pri), rodent (rod), mammalian (mamp), vertebrate (vrtp), and  
eukaryote (eukp) databases, SwissProt, BLOCKS, and other databases which contain  
previously identified and annotated motifs and sequences. Algorithms such as Smith  
30 Waterman which deal with primary sequence patterns and secondary structure gap  
penalties (Smith, T. et al. (1992) Protein Engineering 5:35-51) and programs and

algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul, S.F. (1993) J. Mol. Evol 36:290-300; and Altschul et al. (1990) J. Mol. Biol. 215:403-410), and HMM (Hidden Markov Models; Eddy, S.R. (1996) Cur. Opin. Str. Biol. 6:361-365 and Sonnhammer, E.L.L. et al. (1997) Proteins 28:405-420) were used to assemble and  
5 analyze nucleotide and amino acid sequences. The databases, programs, algorithms, methods and tools are available, well known in the art, and described in Ausubel (supra, unit 7.7), in Meyers, R.A. (1995; Molecular Biology and Biotechnology, Wiley VCH, Inc, New York NY, p 856-853), in documentation provided with software (Genetics Computer Group (GCG), Madison WI), and on the world wide web (www). Two comprehensive  
10 websites which list, describe, and/or link many of the databases and tools are: 1) the www resource in practical sequence analysis ([http://genome.wustl.edu/eddy/bio5495/online\\_resources.html](http://genome.wustl.edu/eddy/bio5495/online_resources.html)), and 2) the bibliography of computational gene recognition (<http://linkage.rockefeller.edu/wli/gene/programs.html>). For example, the first website  
15 links PFAM as a database (<http://genome.wustl.edu/Pfam/>) and as an HMM search tool ([http://genome.wustl.edu/eddy/cgi-bin/hmm\\_page.cgi](http://genome.wustl.edu/eddy/cgi-bin/hmm_page.cgi)).

Table 5 summarizes the databases and tools used herein. The first column of Table 5 shows the tool, program, or algorithm; the second column, the database; the third  
20 column, a brief description; and the fourth column (where applicable), scores for determining the strength of a match between two sequences (the higher the value, the more homologous).

#### IV. Northern Analysis

25 Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; and Ausubel, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST are used to search for identical  
30 or related molecules in nucleotide databases such as GenBank or LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based

hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.

The basis of the search is the product score, which is defined as:  $\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$

5

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of Northern analysis are reported as a list of libraries in which the transcript encoding CECRP occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

15

#### V. Extension of CECRP Encoding Polynucleotides

The nucleic acid sequences of Incyte Clones 037377, 162871, 236062, 1596581, and 1853196, were used to design oligonucleotide primers for extending partial nucleotide sequences to full length. For each nucleic acid sequence, one primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO™ 4.06 (National Biosciences, Plymouth, MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

25

Selected human cDNA libraries (GIBCO BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed

30

to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR™ kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
10	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
	Step 7	Repeat steps 4 through 6 for an additional 15 cycles
	Step 8	94° C for 15 sec
15	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
	Step 11	Repeat steps 8 through 10 for an additional 12 cycles
	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

20

A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQUICK™ (QIAGEN Inc.), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13  $\mu$ l of ligation buffer, 1  $\mu$ l T4-DNA ligase (15 units) and 1  $\mu$ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40  $\mu$ l of appropriate media) were transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of SOC medium. (See, e.g., Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37° C, the *E. coli* mixture was plated

on Luria Bertani (LB) agar (See, e.g., Sambrook, supra, Appendix A, p. 1) containing carbenicillin (2x carb). The following day, several colonies were randomly picked from each plate and cultured in 150  $\mu$ l of liquid LB/2x carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5  $\mu$ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5  $\mu$ l from each sample was transferred into a PCR array.

For PCR amplification, 18  $\mu$ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
15 Step 4	72° C for 90 sec
Step 5	Repeat steps 2 through 4 for an additional 29 cycles
Step 6	72° C for 180 sec
Step 7	4° C (and holding)

20 Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:6 through 10 to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

## VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:6 through 10 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-

art software such as OLIGO™ 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham, Chicago, IL), and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified using a Sephadex™ G-25 superfine  
5 size exclusion dextran bead column (Pharmacia & Upjohn, Kalamazoo, MI). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN, Boston, MA).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred  
10 to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots to film for several hours, hybridization patterns are  
15 compared visually.

## VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array  
20 analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of  
25 complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE™. Full-length  
30 cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present

invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; and Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for  
5 hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

### VIII. Complementary Polynucleotides

Sequences complementary to the CECRP-encoding sequences, or any parts  
10 thereof, are used to detect, decrease, or inhibit expression of naturally occurring CECRP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO™ 4.06 software and the coding sequence of CECRP. To inhibit transcription, a complementary oligonucleotide is  
15 designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the CECRP-encoding transcript.

### 20 IX. Expression of CECRP

Expression and purification of CECRP is achieved using bacterial or virus-based expression systems. For expression of CECRP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are  
25 not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express CECRP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of CECRP in eukaryotic cells is achieved by infecting insect or mammalian  
30 cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of

baculovirus is replaced with cDNA encoding CECRP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera 5 frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, CECRP is synthesized as a fusion protein with, e.g., 10 glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Pharmacia, Piscataway, NJ). Following 15 purification, the GST moiety can be proteolytically cleaved from CECRP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak, Rochester, NY). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN Inc, Chatsworth, CA). Methods for protein 20 expression and purification are discussed in Ausubel, F. M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, ch 10, 16. Purified CECRP obtained by these methods can be used directly in the following activity assay.

#### 25 X. Demonstration of CECRP Activity

CECRP activity is demonstrated by measuring the induction of terminal differentiation or cell cycle progression when CECRP is expressed at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA 30 expression. Vectors of choice include pCMV SPORT™ (Life Technologies, Gaithersburg, MD) and pCR™ 3.1 (Invitrogen, Carlsbad, CA), both of which contain the

cytomegalovirus promoter. 5-10  $\mu\text{g}$  of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2  $\mu\text{g}$  of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP) (Clontech, Palo Alto, CA), CD64, or a CD64-GFP fusion protein. Flow cytometry detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell cycle progression or terminal differentiation. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; up or down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York, NY.

## **XI. Functional Assays**

CECRP function is assessed by expressing the sequences encoding CECRP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT™ (Life Technologies, Gaithersburg, MD) and pCR™ 3.1 (Invitrogen, Carlsbad, CA, both of which contain the cytomegalovirus promoter. 5-10  $\mu\text{g}$  of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2  $\mu\text{g}$  of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP) (Clontech, Palo Alto, CA), CD64, or a CD64-GFP

fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP, and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York, NY.

The influence of CECRP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding CECRP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success, NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding CECRP and other genes of interest can be analyzed by Northern analysis or microarray techniques.

## **XII. Production of CECRP Specific Antibodies**

CECRP substantially purified using polyacrylamide gel electrophoresis (PAGE)(see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the CECRP amino acid sequence is analyzed using LASERGENE™ software (DNASTAR Inc.) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of

appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to KLH  
5 (Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-  
10 iodinated goat anti-rabbit IgG.

### **XIII. Purification of Naturally Occurring CECRP Using Specific Antibodies**

Naturally occurring or recombinant CECRP is substantially purified by immunoaffinity chromatography using antibodies specific for CECRP. An  
15 immunoaffinity column is constructed by covalently coupling anti-CECRP antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing CECRP are passed over the immunoaffinity column, and the  
20 column is washed under conditions that allow the preferential absorbance of CECRP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/CECRP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and CECRP is collected.

### **25 XIV. Identification of Molecules Which Interact with CECRP**

CECRP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled CECRP, washed, and any wells with labeled CECRP complex are assayed. Data  
30 obtained using different concentrations of CECRP are used to calculate values for the number, affinity, and association of CECRP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed  
5 should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	6	037377	HUVENOB01	037377H1 (HUVENOB01), 403002R6 (TMLR3DT01), 510407R6 (MPHGN03), 1520634F1 (BLADTUT04), 3985439H1 (UTRSTUT05)
2	7	162871	ADENINB01	162871H1 (ADENINB01), 162871X4 (ADENINB01), 162871X92 (ADENINB01), 1554775H1 (BLADTUT04)
3	8	236062	SINTNOT02	236062CT1 (SINTNOT02), 236062H1 (SINTNOT02), 1352052H1 (LATRTUT02), 2238411F6 (PANCTUT02), 3015795H1 (MUSCNOT07)
4	9	1596581	BRAINOT14	1477338F1 (CORPNOT02), 1596581F6 (BRAINOT14), 1596581H1 (BRAINOT14), 1596581T1 (BRAINOT14), 1658067H1 (URETTUT01), 2312928H1 (NGANNOT01), 3231214H1 (COTRNOT01), 3590729H1 (293TF5T01)
5	10	1853196	LUNGFET03	108390F1 (AMLBNOT01), 1211009R1 (BRSTNOT02), 1211009T1 (BRSTNOT02), 1391767F1 (THYRNOT03), 1525569F6 (UCMCL5T01), 1706512F6 (DUODNOT02), 1722946F6 (BLADNOT06), 1853196F6 (LUNGFET03)

Table 2

Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Identifying sequences and/or structural motifs	Analytical Methods
1	197	S128 S15 S71 T108 T27 S71		Blimp-1	Blast
2	225	T181 S222 S122	N54	growth response protein	Blast
3	236	S44 S60 S98 S117 S123 S180 T73		Inhibin beta chain signature	Prints
4	351	T45 S165 S179 T247 T339 T90 T339 Y35 Y51	N79	cdc91	Blast
5	757	T184 S367 S6 S22 T31 S43 S81 T99 S130 S158 S162 S163 S186 S188 S271 S277 T287 T289 S323 T343 S370 T432 S488 S499 S207 S277 T298 S370 T419 S474 S488 S499 S528 T532 T539 S609 S624 Y96 Y730	N4 N63 N479 N498	cell cycle progression restoration 8 protein	Blast

Table 3

Seq ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
6	Reproductive (0.294) Gastrointestinal (0.147) Hematopoietic/Immune (0.147)	Cancer (0.500) Inflammation (0.324) Fetal (0.147)	pBluescript
7	Hematopoietic/Immune (0.240) Cardiovascular (0.160) Nervous (0.160)	Cancer (0.480) Inflammation (0.240) Fetal (0.120)	pBluescript
8	Reproductive (0.302) Cardiovascular (0.186) Nervous (0.163)	Cancer (0.651) Inflammation (0.163) Other (0.140)	pBluescript
9	Gastrointestinal (0.167) Nervous (0.167) Reproductive (0.167)	Cancer (0.467) Fetal (0.233) Inflammation (0.200)	pINCY
10	Nervous (0.200) Reproductive (0.200) Cardiovascular (0.153)	Cancer (0.471) Inflammation (0.282) Other (0.106)	pINCY

Table 4

Nucleotide SEQ ID NO:	Library	Library Description
6	HUVENOB01	The HUVENOB01 library was constructed using RNA isolated from unstimulated HUV-EC-C (ATCC CRL 1730) cells. HUV-EC-C is an endothelial cell line derived from the vein of a normal human umbilical cord (ref: PNAS 81:6413).
7	ADENINB01	The ADENINB01 Library was constructed using RNA isolated from inflamed adenoid tissue of a 3-year-old child. (RNA came from Clontech.)
8	SINTNOT02	The SINTNOT02 library was constructed using RNA isolated from the small intestine of a 55-year-old Caucasian female, who died from a subarachnoid hemorrhage.
9	BRAINOT14	The BRAINOT14 Library was constructed using 1 microgram of polyA RNA isolated from brain tissue removed from the left frontal lobe of a 40-year-old female during excision of a cerebral meningeal lesion. Pathology for the associated tumor tissue indicated grade 4 gemistocytic astrocytoma.
10	LUNGFET03	The LUNGFET03 Library was constructed using 1 microgram of polyA RNA isolated from lung tissue removed from a female fetus, who died at 20 weeks' gestation.

TABLE 5

ESTs	Program/algorithm	Databases	Description	Useful Parameters
	Smith Waterman	GenBank	Local alignment algorithm for homology searching	min length = 49 nt <12% uncalled bases
	FASTA	GenBank	Fast nucleotide sequence database searching program for UNIX, VMS	Log likelihood for exact matches is $\sim 10^{-25}$ and for homologs $>10^8$
	BLAST	GenBank	Ultra-fast database searching program for UNIX, VMS C source	
<b>Full Length</b>				
Phred			Reads trace data from sequencing runs, makes base calls for assembly of cDNA sequences, produces quality scores	
Phrap			Quality-score based assembly program for shotgun sequences	match > 56 score > 120
CONSED			Graphical tool for editing Phrap contigs	
GCG Assembly, Motifs, Profilescan, Spscan		GenBank PROSITE	Wisconsin Package Programs for the assembly, editing, and characterization of nucleotide sequences Examines proteins for secretory, signal sequences	>7 strong, 4.5-7 suggestive
GENEMARK			Statistical analysis of nucleotide sequences to identify open reading frame	score > 100, $P < 1e-5$
BLAST		GenBank SwissProt	Ultra-fast database searching program for UNIX, VMS C source	log likelihood > 17
FASTX		GenBank SwissProt	Fast amino acid sequence database searching program for UNIX, VMS	>1300 strong, 1000 - 1300 suggestive, $P < 1e-3$
BLIMPS		BLOCKS PRINTS	Weighted matrix analysis for prediction of protein family	Score > 11 strong, 8 - 10 suggestive
PFAM		PROSITE	Analyses sequences 3-60 amino acids long which correspond to highly conserved regions of a protein family	Score > 11 strong, 8 - 10 suggestive
HMM			Probabilistic approaches and modeling of the primary structure of protein families	Score > 11 strong, 8 - 10 suggestive
McDNAsis Pro			Software for sequence analysis	
LASERGENE			Software programs (EditSeq, MegAlign, PrimerSelect, Protean, SeqMan, etc.) for sequence analysis	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and fragments thereof.  
5
2. A substantially purified variant having at least 90% amino acid identity to the amino acid sequence of claim 1.
- 10 3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.  
15
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is  
20 complementary to the polynucleotide sequence of claim 3.
7. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and fragments thereof.  
25
8. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 7.
9. An isolated and purified polynucleotide having a sequence which is  
30 complementary to the polynucleotide of claim 7.

10. An expression vector comprising at least a fragment of the polynucleotide of claim 3.

11. A host cell comprising the expression vector of claim 10.

5

12. A method for producing a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and fragments thereof, the method comprising the steps of:

10 a) culturing the host cell of claim 11 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

13. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

15

14. A purified antibody which specifically binds to the polypeptide of claim 1.

15. A purified agonist of the polypeptide of claim 1.

20 16. A purified antagonist of the polypeptide of claim 1.

17. A method for treating or preventing a cell proliferation disorder, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 13.

25

18. A method for treating or preventing a cell proliferation disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

30 19. A method for stimulating cell proliferation, the method comprising administering to a cell an effective amount of the pharmaceutical composition of claim 13.

20. A method for treating or preventing an immune disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

5 21. A method for treating or preventing an immune disorder, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 13.

22. A method for detecting a polynucleotide encoding the polypeptide  
10 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and fragments thereof in a biological sample, the method comprising the steps of:

(a) hybridizing the polynucleotide of claim 6 to at least one of the nucleic acids in the biological sample, thereby forming a hybridization complex;

15 and

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide encoding the polypeptide in the biological sample.

20 23. The method of claim 22 wherein the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to hybridization.

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.  
 BANDMAN, Olga  
 LAL, Preeti  
 TANG, Y. Tom  
 CORLEY, Neil C.  
 GUEGLER, Karl J.  
 BAUGHN, Mariah R.  
 PATTERSON, Chandra

<120> CELL CYCLE REGULATION PROTEINS

<130> PF-0531 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/088,695

<151> 1998-06-08

<160> 35

<170> PERL Program

<210> 1

<211> 197

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte clone 037377

<400> 1

Met	Leu	Val	Leu	Pro	Ser	Pro	Cys	Pro	Gln	Pro	Leu	Ala	Phe	Ser
1				5					10					15
Ser	Val	Glu	Thr	Met	Glu	Gly	Pro	Pro	Arg	Arg	Thr	Cys	Arg	Ser
				20					25					30
Pro	Glu	Pro	Gly	Pro	Ser	Ser	Ser	Ile	Gly	Ser	Pro	Gln	Ala	Ser
				35					40					45
Ser	Pro	Pro	Arg	Pro	Asn	His	Tyr	Leu	Leu	Ile	Asp	Thr	Gln	Gly
				50					55					60
Val	Pro	Tyr	Thr	Val	Leu	Val	Asp	Glu	Glu	Ser	Gln	Arg	Glu	Pro
				65					70					75
Gly	Ala	Ser	Gly	Ala	Pro	Gly	Gln	Lys	Lys	Cys	Tyr	Ser	Cys	Pro
				80					85					90
Val	Cys	Ser	Arg	Val	Phe	Glu	Tyr	Met	Ser	Tyr	Leu	Gln	Arg	His
				95					100					105
Ser	Ile	Thr	His	Ser	Glu	Val	Lys	Pro	Phe	Glu	Cys	Asp	Ile	Cys
				110					115					120
Gly	Lys	Ala	Phe	Lys	Arg	Ala	Ser	His	Leu	Ala	Arg	His	His	Ser
				125					130					135
Ile	His	Leu	Ala	Gly	Gly	Gly	Arg	Pro	His	Gly	Cys	Pro	Leu	Cys
				140					145					150

Pro Arg Arg Phe Arg Asp Ala Gly Glu Leu Ala Gln His Ser Arg  
 155 160 165  
 Val His Ser Gly Glu Arg Pro Phe Gln Cys Pro His Cys Pro Arg  
 170 175 180  
 Arg Phe Met Glu Gln Asn Thr Leu Gln Lys His Thr Arg Trp Lys  
 185 190 195  
 His Pro

<210> 2  
 <211> 225  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 162871

<400> 2  
 Met Ala Glu Gly Glu Thr Glu Ser Pro Gly Pro Lys Lys Cys Gly  
 1 5 10 15  
 Pro Tyr Ile Ser Ser Val Thr Ser Gln Ser Val Asn Leu Met Ile  
 20 25 30  
 Arg Gly Val Val Leu Phe Phe Ile Gly Val Phe Leu Ala Leu Val  
 35 40 45  
 Leu Asn Leu Leu Gln Ile Gln Arg Asn Val Thr Leu Phe Pro Pro  
 50 55 60  
 Asp Val Ile Ala Ser Ile Phe Ser Ser Ala Trp Trp Val Pro Pro  
 65 70 75  
 Cys Cys Gly Thr Ala Ser Ala Val Ile Gly Leu Leu Tyr Pro Cys  
 80 85 90  
 Ile Asp Arg His Leu Gly Glu Pro His Lys Phe Lys Arg Glu Trp  
 95 100 105  
 Ser Ser Val Met Arg Cys Val Ala Val Phe Val Gly Ile Asn His  
 110 115 120  
 Ala Ser Ala Lys Val Asp Phe Asp Asn Asn Ile Gln Leu Ser Leu  
 125 130 135  
 Thr Leu Ala Ala Leu Ser Ile Gly Leu Trp Trp Thr Phe Asp Arg  
 140 145 150  
 Ser Arg Ser Gly Phe Gly Leu Gly Val Gly Ile Ala Phe Leu Ala  
 155 160 165  
 Thr Val Val Thr Gln Leu Leu Val Tyr Asn Gly Val Tyr Gln Tyr  
 170 175 180  
 Thr Ser Pro Asp Phe Leu Tyr Val Arg Ser Trp Leu Pro Cys Ile  
 185 190 195  
 Phe Phe Ala Gly Gly Ile Thr Met Gly Asn Ile Gly Arg Gln Leu  
 200 205 210  
 Ala Met Tyr Glu Cys Lys Val Ile Ala Glu Lys Ser His Gln Glu  
 215 220 225

<210> 3  
 <211> 236  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 236062

<400> 3  
 Met Leu Ser Lys Gly Leu Lys Arg Lys Arg Glu Glu Glu Glu Glu  
   1                  5                  10                  15  
 Lys Glu Pro Leu Ala Val Asp Ser Trp Trp Leu Asp Pro Gly His  
                   20                  25                  30  
 Ala Ala Val Ala Gln Ala Pro Pro Ala Val Ala Ser Ser Ser Leu  
                   35                  40                  45  
 Phe Asp Leu Ser Val Leu Lys Leu His His Ser Leu Gln Gln Ser  
                   50                  55                  60  
 Glu Pro Asp Leu Arg His Leu Val Leu Val Val Asn Thr Leu Arg  
                   65                  70                  75  
 Arg Ile Gln Ala Ser Met Ala Pro Ala Ala Ala Leu Pro Pro Val  
                   80                  85                  90  
 Pro Ser Pro Pro Ala Ala Pro Ser Val Ala Asp Asn Leu Leu Ala  
                   95                  100                 105  
 Ser Ser Asp Ala Ala Leu Ser Ala Ser Met Ala Ser Leu Leu Glu  
                  110                 115                 120  
 Asp Leu Ser His Ile Glu Gly Leu Ser Gln Ala Pro Gln Pro Leu  
                  125                 130                 135  
 Ala Asp Glu Gly Pro Pro Gly Arg Ser Ile Gly Gly Ala Ala Pro  
                  140                 145                 150  
 Ser Leu Gly Ala Leu Asp Leu Leu Gly Pro Ala Thr Gly Cys Leu  
                  155                 160                 165  
 Leu Asp Asp Gly Leu Glu Gly Leu Phe Glu Asp Ile Asp Thr Ser  
                  170                 175                 180  
 Met Tyr Asp Asn Glu Leu Trp Ala Pro Ala Ser Glu Gly Leu Lys  
                  185                 190                 195  
 Pro Gly Pro Glu Asp Gly Pro Gly Lys Glu Glu Ala Pro Glu Leu  
                  200                 205                 210  
 Asp Glu Ala Glu Leu Asp Tyr Leu Met Asp Val Leu Val Gly Thr  
                  215                 220                 225  
 Gln Ala Leu Glu Arg Pro Pro Gly Pro Gly Arg  
                  230                 235

<210> 4  
 <211> 351  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1596581

<400> 4  
 Met Ile Thr Asp Ala Leu Thr Ala Ile Ala Leu Tyr Phe Ala Ile  
   1                  5                  10                  15  
 Gln Asp Phe Asn Lys Val Val Phe Lys Lys Gln Lys Leu Leu Leu

	20		25		30
Glu Leu Asp Gln Tyr Ala Pro Asp Val Ala Glu Leu Ile Arg Thr					
	35		40		45
Pro Met Glu Met Arg Tyr Ile Pro Leu Lys Val Ala Leu Phe Tyr					
	50		55		60
Leu Leu Asn Pro Tyr Thr Ile Leu Ser Cys Val Ala Lys Ser Thr					
	65		70		75
Cys Ala Ile Asn Asn Thr Leu Ile Ala Phe Phe Ile Leu Thr Thr					
	80		85		90
Ile Lys Gly Ser Ala Phe Leu Ser Ala Ile Phe Leu Ala Leu Ala					
	95		100		105
Thr Tyr Gln Ser Leu Tyr Pro Leu Thr Leu Phe Val Pro Gly Leu					
	110		115		120
Leu Tyr Leu Leu Gln Arg Gln Tyr Ile Pro Val Lys Met Lys Ser					
	125		130		135
Lys Ala Phe Trp Ile Phe Ser Trp Glu Tyr Ala Met Met Tyr Val					
	140		145		150
Gly Ser Leu Val Val Ile Ile Cys Leu Ser Phe Phe Leu Leu Ser					
	155		160		165
Ser Trp Asp Phe Ile Pro Ala Val Tyr Gly Phe Ile Leu Ser Val					
	170		175		180
Pro Asp Leu Thr Pro Asn Ile Gly Leu Phe Trp Tyr Phe Phe Ala					
	185		190		195
Glu Met Phe Glu His Phe Ser Leu Phe Phe Val Cys Val Phe Gln					
	200		205		210
Ile Asn Val Phe Phe Tyr Thr Ile Pro Leu Ala Ile Lys Leu Lys					
	215		220		225
Glu His Pro Ile Phe Phe Met Phe Ile Gln Ile Ala Val Ile Ala					
	230		235		240
Ile Phe Lys Ser Tyr Pro Thr Val Gly Asp Val Ala Leu Tyr Met					
	245		250		255
Ala Phe Phe Pro Val Trp Asn His Leu Tyr Arg Phe Leu Arg Asn					
	260		265		270
Ile Phe Val Leu Thr Cys Ile Ile Ile Val Cys Ser Leu Leu Phe					
	275		280		285
Pro Val Leu Trp His Leu Trp Ile Tyr Ala Gly Ser Ala Asn Ser					
	290		295		300
Asn Phe Phe Tyr Ala Ile Thr Leu Thr Phe Asn Val Gly Gln Ile					
	305		310		315
Leu Leu Ile Ser Asp Tyr Phe Tyr Ala Phe Leu Arg Arg Glu Tyr					
	320		325		330
Tyr Leu Thr His Gly Leu Tyr Leu Thr Ala Lys Asp Gly Thr Glu					
	335		340		345
Ala Met Leu Val Leu Lys					
	350				

<210> 5

<211> 757

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte clone 1853196

<400> 5

Met	Ser	Glu	Asn	Ser	Ser	Asp	Ser	Asp	Ser	Ser	Cys	Gly	Trp	Thr
1				5					10					15
Val	Ile	Ser	His	Glu	Gly	Ser	Asp	Ile	Glu	Met	Leu	Asn	Ser	Val
				20					25					30
Thr	Pro	Thr	Asp	Ser	Cys	Glu	Pro	Ala	Pro	Glu	Cys	Ser	Ser	Leu
				35					40					45
Glu	Gln	Glu	Glu	Leu	Gln	Ala	Leu	Gln	Ile	Glu	Gln	Gly	Glu	Ser
				50					55					60
Ser	Gln	Asn	Gly	Thr	Val	Leu	Met	Glu	Glu	Thr	Ala	Tyr	Pro	Ala
				65					70					75
Leu	Glu	Glu	Thr	Ser	Ser	Thr	Ile	Glu	Ala	Glu	Glu	Gln	Lys	Ile
				80					85					90
Pro	Glu	Asp	Ser	Ile	Tyr	Ile	Gly	Thr	Ala	Ser	Asp	Asp	Ser	Asp
				95					100					105
Ile	Val	Thr	Leu	Glu	Pro	Pro	Lys	Leu	Glu	Glu	Ile	Gly	Asn	Gln
				110					115					120
Glu	Val	Val	Ile	Val	Glu	Glu	Ala	Gln	Ser	Ser	Glu	Asp	Phe	Asn
				125					130					135
Met	Gly	Ser	Ser	Ser	Ser	Ser	Gln	Tyr	Thr	Phe	Cys	Gln	Pro	Glu
				140					145					150
Thr	Val	Phe	Ser	Ser	Gln	Pro	Ser	Asp	Asp	Glu	Ser	Ser	Ser	Asp
				155					160					165
Glu	Thr	Ser	Asn	Gln	Pro	Ser	Pro	Ala	Phe	Arg	Arg	Arg	Arg	Ala
				170					175					180
Arg	Lys	Lys	Thr	Val	Ser	Ala	Ser	Glu	Ser	Glu	Asp	Arg	Leu	Val
				185					190					195
Ala	Glu	Gln	Glu	Thr	Glu	Pro	Ser	Lys	Glu	Leu	Ser	Lys	Arg	Gln
				200					205					210
Phe	Ser	Ser	Gly	Leu	Asn	Lys	Cys	Val	Ile	Leu	Ala	Leu	Val	Ile
				215					220					225
Ala	Ile	Ser	Met	Gly	Phe	Gly	His	Phe	Tyr	Gly	Thr	Ile	Gln	Ile
				230					235					240
Gln	Lys	Arg	Gln	Gln	Leu	Val	Arg	Lys	Ile	His	Glu	Asp	Glu	Leu
				245					250					255
Asn	Asp	Met	Lys	Asp	Tyr	Leu	Ser	Gln	Cys	Gln	Gln	Glu	Gln	Glu
				260					265					270
Ser	Phe	Ile	Asp	Tyr	Lys	Ser	Leu	Lys	Glu	Asn	Leu	Ala	Arg	Cys
				275					280					285
Trp	Thr	Leu	Thr	Glu	Ala	Glu	Lys	Met	Ser	Phe	Glu	Thr	Gln	Lys
				290					295					300
Thr	Asn	Leu	Ala	Thr	Glu	Asn	Gln	Tyr	Leu	Arg	Val	Ser	Leu	Glu
				305					310					315
Lys	Glu	Glu	Lys	Ala	Leu	Ser	Ser	Leu	Gln	Glu	Glu	Leu	Asn	Lys
				320					325					330
Leu	Arg	Glu	Gln	Ile	Arg	Ile	Leu	Glu	Asp	Lys	Gly	Thr	Ser	Thr
				335					340					345
Glu	Leu	Val	Lys	Glu	Asn	Gln	Lys	Leu	Lys	Gln	His	Leu	Glu	Glu
				350					355					360
Glu	Lys	Gln	Lys	Lys	His	Ser	Phe	Leu	Ser	Gln	Arg	Glu	Thr	Leu
				365					370					375
Leu	Thr	Glu	Ala	Lys	Met	Leu	Lys	Arg	Glu	Leu	Glu	Arg	Glu	Arg
				380					385					390
Leu	Val	Thr	Thr	Ala	Leu	Arg	Gly	Glu	Leu	Gln	Gln	Leu	Ser	Gly
				395					400					405
Ser	Gln	Leu	His	Gly	Lys	Ser	Asp	Ser	Pro	Asn	Val	Tyr	Thr	Glu
				410					415					420

Lys Lys Glu Ile Ala Ile Leu Arg Glu Arg Leu Thr Glu Leu Glu	425	430	435
Arg Lys Leu Thr Phe Glu Gln Gln Arg Ser Asp Leu Trp Glu Arg	440	445	450
Leu Tyr Val Glu Ala Lys Asp Gln Asn Gly Lys Gln Gly Thr Asp	455	460	465
Gly Lys Lys Lys Gly Gly Arg Gly Ser His Arg Ala Lys Asn Lys	470	475	480
Ser Lys Glu Thr Phe Leu Gly Ser Val Lys Glu Thr Phe Asp Ala	485	490	495
Met Lys Asn Ser Thr Lys Glu Phe Val Arg His His Lys Glu Lys	500	505	510
Ile Lys Gln Ala Lys Glu Ala Val Lys Glu Asn Leu Lys Lys Phe	515	520	525
Ser Asp Ser Val Lys Ser Thr Phe Arg His Phe Lys Asp Thr Thr	530	535	540
Lys Asn Ile Phe Asp Glu Lys Gly Asn Lys Arg Phe Gly Ala Thr	545	550	555
Lys Glu Ala Ala Glu Lys Pro Arg Thr Val Phe Ser Asp Tyr Leu	560	565	570
His Pro Gln Tyr Lys Ala Pro Thr Glu Asn His His Asn Arg Gly	575	580	585
Pro Thr Met Gln Asn Asp Gly Arg Lys Glu Lys Pro Val His Phe	590	595	600
Lys Glu Phe Arg Lys Asn Thr Asn Ser Lys Lys Cys Ser Pro Gly	605	610	615
His Asp Cys Arg Glu Asn Ser His Ser Phe Arg Lys Ala Cys Ser	620	625	630
Gly Val Phe Asp Cys Ala Gln Gln Glu Ser Met Ser Leu Phe Asn	635	640	645
Thr Val Val Asn Pro Ile Arg Met Asp Glu Phe Arg Gln Ile Ile	650	655	660
Gln Arg Tyr Met Leu Lys Glu Leu Asp Thr Phe Cys His Trp Asn	665	670	675
Glu Leu Asp Gln Phe Ile Asn Lys Phe Phe Leu Asn Gly Val Phe	680	685	690
Ile His Asp Gln Lys Leu Phe Thr Asp Phe Val Asn Asp Val Lys	695	700	705
Asp Tyr Leu Arg Asn Met Lys Glu Tyr Glu Val Asp Asn Asp Gly	710	715	720
Val Phe Glu Lys Leu Asp Glu Tyr Ile Tyr Arg His Phe Phe Gly	725	730	735
His Thr Phe Ser Pro Pro Tyr Gly Pro Arg Ser Val Tyr Ile Lys	740	745	750
Pro Cys His Tyr Ser Ser Leu	755		

&lt;210&gt; 6

&lt;211&gt; 1378

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte clone 037377

<400> 6  
 ggctcttctc tgcgtgtgcg tgcacgttgg gtgctggggg gtggagaccg gatcttcctc 60  
 gcttgggtac tttcctctcg gtgtgtggtt ctggccggag ccgtttcgcg acggccccgg 120  
 cgccccgcc caaccttctc tccttagacc ctcttctctc ctttcggctt ctctctttcg 180  
 gccgcgccc ccagttcctg gggcacaccc agaggtcccc ttctcgccgc cgcttcaac 240  
 tgcgagggta gcccggggcc gcttggagtc gcccggacct gagaggctgc tgcactgggc 300  
 ctcagccagc cctccggatg ctgggtgctgc catccccctg ccctcagcct ctggcatttt 360  
 cctccgttga gaccatggag ggcctcccc gtctggactg ccgctcccc gaacctggac 420  
 cttcctctc catcggatct ccccaggctt catctctctc aaggcccaac cactacctgc 480  
 ttattgacac tcaggggtgtc ccctacacag tgctgggtgga cgaggagtca cagagggagc 540  
 cagggggccag tggggctcca ggcagaaaa agtgctacag ctgcccctg tgctcaaggg 600  
 tcttcgagta catgtcctac cttcagcgac acagcatcac cactcggag gtaaagccct 660  
 tcgagtgtga catctgtggg aaggcattca agcgcgccag cacttggca cggcaccatt 720  
 ccattcacct ggcgggtggt gggcgcccc acggctgccc gctctgcct cgccgcttcc 780  
 gggatgcggg tgagctggcc cagcacagcc ggggtgactc tggggaacgc ccgtttcagt 840  
 gtccacactg ccctcgccgc tttatggagc agaacacact gcagaaacac acgcgggtgga 900  
 agcatccatg agccgggctg ccgggtgccc caggtaccac aggactttgc agggagcctg 960  
 gactcctgtc cagacacctg gtgagagcct gaggtggtg ttcagggccc tggacacaga 1020  
 cacagagcag ccgcatctca aaggcagagc cctgcctgaa ggaggaatcc gtgagtaatc 1080  
 ttcaggtcct ccgtgttctg gagctgagat gggaatgagc ccctacacag aatggagtcc 1140  
 tctagcctaa agatatcagc tgttccatgg cagagcctg actggatgga ggtggggagt 1200  
 gtggtgtgta aagtctctgg cctcataaaa ggtggctgtg ggtcgtcagg aatctgcgcc 1260  
 atcttctctg ggcttctgcg ctgttgttgg ggaagggacc ccagtctgc ctccacccc 1320  
 ccaaccaggc ctgagactga tcaaaaaa aacacgtttc cactctgaa aaaaaaaaa 1378

<210> 7  
 <211> 1207  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 162871

<400> 7  
 gggcggagtt gtgggagtgg aggaggaaga ggcggtaggg ggtacggggg ctggtcccag 60  
 aagatggcgg aggcggggga tttctggtag gtcctacttt aggacaagat gtggtaccgt 120  
 tgaagcgtca gtctttgatt cacagacagt tgagcttttc agctgggaag cctttccatt 180  
 tttttttttt ttaacggctt tctgaaccta tgaaaccatg gcagaaggag agacagagtc 240  
 acctggggccc aaaaagtgtg gcccatatat ttcactctgc actagccaga gtgtgaactt 300  
 gatgattcga ggagtagtgc tattttttat tggagtattt cttgcattag tgttaaattt 360  
 acttcagatt cagagaaatg tgacgctctt tccacctgat gtgattgcaa gcatcttttc 420  
 ttctgcatgg tgggtacccc catgctgtgg cacggcttct gctgtgattg ggttattata 480  
 cccctgcatt gacagacatc taggagaacc acataaattt aaaagagagt ggtccagtgt 540  
 aatgcgggtg ttagcagtct ttgttggat aatcatgcc agtgctaaag tggatttoga 600  
 taacaacata cagttgtctc tcacactggc tgcactatcc attggactgt ggtggacttt 660  
 tgatagatct agaagtgggt ttggccttgg agtaggaatt gccttcttgg caactgtggt 720  
 cactcaactg ctagtatata atggtgttta ccaatataca tctccagatt tctctatgt 780  
 tegtcttgg ttaccatgta tattttttgc tggaggcata acaatgggaa acatgggtcg 840  
 acaactggca atgtacgaat gtaaagtat cgcagaaaaa tctcatcagg aatgaagaag 900  
 gcaaaaaata tctttgtac agaaaagcaa gatgaaaagg atgtgaaatg gtagatatac 960  
 caacaaaact tcagactgta aaattgccag gatgcagttt tccccttgat tggcgtgtgt 1020  
 gtatatatgg aataaatata tatatacaca cacacatatt actgcaatct gtgattgctt 1080  
 catctgtaaa tcagttgtaa acctttacat atttgactta aataactgta agatatatat 1140  
 gtactacatt aaaaagtgtt gattaataga tgaaattttt aaattaattt tttaaaaacat 1200

gcccata

1207

<210> 8  
 <211> 1192  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 236062

<400> 8  
 gtgagccgga gtcagaactg cgtctcgcga cccagggcgcg ggtttccgga ggacagccaa 60  
 caagcgatgc tgccgccgcc gtttcctgat tgggtgtggg tggctacctc ttcgttctga 120  
 ttggccgcta gtgagcaaga tgctgagcaa gggctctgaag cgaaacggg aggaggagga 180  
 ggagaaggaa cctctggcag tcgactcctg gtggctagat cctggccacg cagcgggtggc 240  
 acaggcacc cggcccgagg cctctagctc cctctttgac ctctcagtgc tcaagctcca 300  
 ccacagcctg cagcagagtg agccggacct gcggcacctg gtgctggctg tgaacactct 360  
 gcggcgcac caggcgtcca tggcaccgc ggctgccctg ccacctgtgc ctgcccacc 420  
 tgcagcccc agtgtggctg acaacttact ggcaagctcg gacgtgccc tttcagctc 480  
 catggccagc ctctggagg acctcagcca cattgagggc ctgagtcagg ctccccacc 540  
 cttggcagac gaggggccac caggccgtag catcggggga gcagcgcca gcctgggtgc 600  
 cttggacctg ctgggcccag ccaactggctg tctactggac gatgggcttg agggcctgtt 660  
 tgaggatatt gacacctcta tgtatgacaa tgaactttgg gcaccagcct ctgagggcct 720  
 caaaccaggc cctgaggatg ggccgggcaa ggaggaagct ccggagctgg acgaggccga 780  
 attggactac ctcatggatg tggatgggtg cacacaggca ctggagcgac cgccggggcc 840  
 agggcgctga gccctcgtgc tggaatggtt gtctgggtatc tgaactgagc ctgctggctg 900  
 gaccaactgt cctcgaaaag acacagctgg ctccctagt acagagaaca gggcttgggc 960  
 cactttggag agacagaatc tagtcctggg caacttcaca tccgtcctcc tgtctcaggg 1020  
 ctggcagggg gagcctggaa ttaccctcta gtgatggaat gacagggctt ggtggggact 1080  
 gaattccctg gccctgggtt catagcttgg gctgttctct ctctgatacg ggaagagacc 1140  
 ccaatcagat ttttcaaatt aaagccagtc ctgggaaatc tcaaaaaaaaa aa 1192

<210> 9  
 <211> 1631  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1596581

<400> 9  
 cggacgcgtg ggtgctgggt gtggctgtga cagtgcgggc ggccttgctc cgctccagtc 60  
 tggccgagtt catttccgag cgggtggagg tgggtgcccc actgagctct tggagagag 120  
 tggttgaagg cctttcactg ttggacttgg gagtatctcc gtattctgga gcagtattc 180  
 atgaaactcc attaataata tacctctttc atttccaat tgactatgct gaattgggtg 240  
 ttatgataac tgatgcactc actgctattg cctgtattt tgcaatccag gacttcaata 300  
 aagttgtggt taaaaagcag aaactcctcc tagaactgga ccagtatgcc ccagtatgg 360  
 ccgaactcat ccggaccctt atggaaatgc gttacatccc tttgaaagtg gccctgttct 420  
 atctcttaaa tccttacacg atttgtctt gtgttgccaa gtctacctgt gccatcaaca 480  
 acaccctcat tgctttcttc attttgacta cgataaaagg cagtgtttc ctgagtgcta 540  
 tttttcttgc cttagcgaca taccagtctc tgtaccact cacctgtttt gtcccaggac 600  
 tcctctatct cctccagcgg cagtacatac ctgtgaaaat gaagagcaaa gccttctgga 660

```

tcttttcttg ggagtatgcc atgatgtatg tgggaagcct agtggtaatc atttgctct 720
ccttcttctt tctcagctct tgggatttca tccccgcagt ctatggcttt atactttctg 780
ttccagatct cactccaaac attggtcttt tctggtaact ctttgcagag atgtttgagc 840
acttcagcct cttctttgta tgtgtgtttc agatcaacgt cttcttctac accatcccct 900
tagccataaa gctaaaggag caccccatct tcttcatgtt tatccagatc gctgtcatcg 960
ccatctttaa gtcctaccg acagtggggg acgtggcgct ctacatggcc ttcttccccg 1020
tgtggaacca tctctacaga ttcttgagaa acatctttgt cctcacctgc atcatcatcg 1080
tctgttcctt gctcttccct gtctgtggc acctctggat ttatgcagga agtgccaact 1140
ctaatttctt ttatgccatc aactgacct tcaacgttgg gcagatcctg ctcatctctg 1200
attacttcta tgccttctg cggcgggagt actacctcac acatggcctc tacttgaccg 1260
ccaaggatgg cacagaggcc atgctcgtgc tcaagtaggc ctggctggca cagggctgca 1320
tggacctcag ggggctgtgg ggcagaagc tgggccaagc cctccagcca gagttgccag 1380
caggcgagtg cttgggcaga agaggttcga gtccagggtc acaagtctct ggtacaaaa 1440
gggacctatg gctgactgac agcaaggcct atggggaaga actgggagct cccaacttg 1500
gacccccacc ttgtggctct gcacaccaag gagccccctc ccagacagga aggagaagag 1560
gcaggtgagc agggcttgtt agattgtggc tacttaataa atgttttttg ttatgaagtc 1620
taaaaaaaaa a 1631

```

```

<210> 10
<211> 3006
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte clone 1853196

```

```

<400> 10
ttggcgccc agctgtgacc gccgccactg gggcagccag cacaatcggg cggaggtggc 60
gctgcccctt cagacctgaa agatgtctga aaattccagt gacagtgatt catcttgtgg 120
ttggactgtc atcagtcatg aggggtcaga tatagaaatg ttgaattctg tgacccccac 180
tgacagctgt gagccccccc cagaatgttc atctttagag caagaggagc ttcaagcatt 240
gcagatagag caaggagaaa gcagccaaaa tggcacagtg cttatggaag aaactgctta 300
tccagctttg gaggaacca gctcaacaat tgaggcagag gaacaaaaga taccgaaga 360
cagtatctat attggaactg ccagtgatga ttctgatatt gttacccttg agccacctaa 420
gttagaagaa attggaatc aagaagttgt cattgttgaa gaagcacaga gttcagaaga 480
ctttaacatg ggctcttctt ctagcagcca gtatacttc tgtcagccag aaactgtatt 540
ttcatctcag cctagtgatg atgaatcaag tagtgatgaa accagtaatc agccagtc 600
tgcttttaga cgacgccgtg ctaggaagaa gaccgttctt gcttcagaat ctgaagaccg 660
gctagttgct gaacaagaaa ctgaaccttc taaggagttg agtaaactgc agttcagtag 720
tggcttcaat aagtgtgtta tacttgcttt ggtgattgca atcagcatgg gatttggcca 780
tttctatggc acaattcaga ttcagaagcg tcaacagtta gtcagaaaga tacatgaaga 840
tgaattgaat gatatgaag attatctttc ccagtgtcaa caggaacaag aatcttttat 900
agattataag tcattgaaag aaaatcttgc aagggtgttg aacttactg aagcagagaa 960
gatgtccttt gaaactcaga aaacgaacct tgetacagaa aatcagtatt taagagtatc 1020
cctggagaag gaagaaaaag ccttatcctc attacaggaa gagttaaca aactaagaga 1080
acagattaga atattggaag ataaagggac aagtactgaa ttagttaaag aaatcagaa 1140
acttaagcag catttgaag aggaaaagca gaaaaaacac agctttctta gtcaaagga 1200
gactctgttg acagaagcaa agatgctaaa gagagaactg gagagagaac gactagtaac 1260
tacggcttta aggggggaac tccagcagtt aagtgttagt cagttacatg gcaagtcaga 1320
ttctcccaat gtatatactg aaaaaagga aatagcaatc ttacgggaaa gactcactga 1380
gtggaacgg aagctaacct tcgaacagca gcgttctgat ttgtgggaaa gattgtatgt 1440
tgaggcaaaa gatcaaatg gaaaacaagg aacagatgga aaaaagaaag ggggcagagg 1500
aagccacagg gctaaaaata agtcaaaagga aacatttttg ggttcagtta aggaaacatt 1560
tgatgccatg aagaattcta ccaaggagtt tgtaaggcat cataaagaga aaattaagca 1620

```

```

ggctaaagaa gctgtgaagg aaaatctgaa aaaattctca gattcagtta aatccacttt 1680
cagacacttt aaagatacca ccaagaatat ctttgatgaa aagggtaata aaagatttgg 1740
tgctacaaaa gaagcagctg aaaaaccaag aacagttttt agtgactatt tacatccaca 1800
gtataaggca cctacagaaa accatcataa tagaggcctt actatgcaaa atgatggaag 1860
gaaagaaaag ccagttcact ttaaagaatt cagaaaaaat acaaattcaa agaaatgcag 1920
tcctgggcat gattgtagag aaaattctca ttctttcaga aaggcttggt ctgggtgtatt 1980
tgattgtgct caacaagagt ccatgagcct ttttaacaca gtgggtgaatc ctataaggat 2040
ggatgaatth agacagataa ttcaaaggta catgttaaaa gaactggata ctttttgtca 2100
ctggaacgaa cttgatcagt tcatcaataa gtttttctta aacgggtgtct ttatacatga 2160
tcagaagctc ttcactgact ttgttaatga tgtaaagat tatcttagaa acatgaagga 2220
atatgaagta gataatgatg gagtatttga gaagttggat gaatatatat atagacactt 2280
ctttggtcac actttttccc ctccatatgg acccaggtcg gtttacataa aaccgtgtca 2340
ttacagtagt ttgtaacatt tgtagattgg atagcatttt tatgatttga tgagtttctt 2400
gtaaggttac cgtttctaag agttgtgctt tatggccact gagagaattc agaataaatt 2460
gaaagatgga gtctaaaaat tattagctgt taciaatgga acatttcatt ataacgtgat 2520
cactttgact tgagcaaatg gtttaatttt tatcttaaaa atcagttaag aatatataaa 2580
atcctacttt ggccaagttt gtttcttttc attatagttt atatgaaaag atcaccttaa 2640
gtgaaattat tttcttttaa tcttttatgt atttattcac ttttggaagc taggaatgag 2700
caacacaaat tttactctga agtcagaaga gctcatatat aataattcta atgtcccacc 2760
tattttcact tgtccattcc atgtaccagc ttagttatga tacttagtca cataattatc 2820
ttgataaag gtagaggcac aaagaggcaa actaagcaag tcaaattcta atgtgtgtac 2880
tcataataa ttttttatcc attttcatct ttatattctg taacatgaaa cttacctaata 2940
cttcaaagt tagcttcatt ttttaccttt gaaatactta atctttctga ataaatataa 3000
tgtgta 3006

```

```

<210> 11
<211> 684
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> unsure
<222> 269, 285, 295, 312, 366, 375, 378, 397, 406, 428, 495, 501, 503
<221> unsure
<222> 586, 592, 610, 613, 643
<223> a or g or c or t, unknown, or other

```

```

<220>
<221> misc_feature
<223> Incyte clone 108390F1

```

```

<400> 11
cagtatatac attgggagaa tctgacttgc catgtaactg actaccactt aactgctgga 60
gttccccctt taaagccgta gttactagtc gttctctctc cagttctctc tttagcatct 120
ttgctttctgt caacagagtc tccctttgac taagaaagct gtgttttttc tgcttttctt 180
cttccaaatg ctgcttaagt ttctgatttt cttaactaa ttcagtactt gtccctttat 240
cttccaatat tctaactctgt tctcttagnt tgtttaactc ttcngtaat gaggntaagg 300
ctttttcttc cntctccagg gatactctta aatactgatt ttctgtagca aggttcgttt 360
ctgagnttca aaggncanct tctctgcttc agtaagnctc caacancttg caagatttct 420
ttcaatgnct tataatctat aaaagttctt gttcccgttg acacggggaa ggtaatcctc 480
atatcatcaa ttcanettca ngnatctttc tgactaactg ttgacgggtc tgaatctgaa 540
tgtgccatag gaatggccaa atcccagctt gattgcaatc accaangcaa gnataacaca 600
cttattgggn ccnctactga actgacgggtt actcaactcc ttnggagggg cagttcttgt 660
tcagcaacta gccggtcttc agat 684

```

<210> 12  
 <211> 416  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1211009R1

<400> 12  
 aagaattcta ccaaggagtt tgtaaggcat cataaagaga aaattaagca ggctaaagaa 60  
 gctgtgaagg aaaatctgaa aaaattctca gattcagtta aatccacttt cagacacttt 120  
 aaagatacca ccaagaatat ctttgatgaa aagggttaata aaagatttgg tgctacaaaa 180  
 gaagcagctg aaaaaccaag aacagttttt agtgactatt tacatccaca gtataaggca 240  
 cctacagaaa accatcataa tagaggccct actatgcaaa atgatggaag gaaagaaaag 300  
 ccagttcact ttaaagaatt cagaaaaaat acaaattcaa agaaatgcag tcctgggcat 360  
 gattgtagag aaaattctca ttctttcaga aaggcttgtt ctggtgtatt tgattg 416

<210> 13  
 <211> 609  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 25, 152, 166, 169, 173, 174, 180, 183, 186, 192, 193, 198, 200  
 <221> unsure  
 <222> 205, 220, 230, 233, 236, 243, 246, 251, 285, 307, 309, 310, 317  
 <221> unsure  
 <222> 319, 329, 344, 345, 377, 475, 485, 556, 573, 583, 594  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1211009T1

<400> 13  
 aagaacatta tatttattca gaaanattaa gtatttcaaa ggtaaaaaat gaagctaaca 60  
 tttgaagatt aggtaagttt catggttacag aatataaaga tgaaaatgga taaaaaatta 120  
 ttatgaagta cacacattag aatttgactt gnttagtttg cctctntgng cennnacctn 180  
 tancanaggt anntatgngn ctaantatca taactaagcn ggtacatggn atnganaagt 240  
 ganaanaggt nggacattag aaattattat atatgagctc ttctnacttc agagtaaaaat 300  
 ttgtgtngnn cattccnanc ttccaaaant gaataaatac atannagatt aaaggaaaat 360  
 aatttcactt aagggtntct tttcatataa actataatga gaagaaacaa acttggccaa 420  
 agtaggattt tatatattct taactgattt ttaagataga aaattaaacc atttntctca 480  
 gtcanaagtga tcacgttata atgaaatggt ccatttgtaa cagctaataa tttttagact 540  
 ccatctttca atttantctg aattctctca gtngccataa agncaactct tagnaacggg 600  
 accttcaag 609

<210> 14  
 <211> 189  
 <212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte clone 1352052H1

<400> 14

```
cttcacatoc gtcctcctgt ctcagggctg gcagggggag cctggaatta cccctagtg 60
atggaatgac agggctctgt ggggactgaa ttccctggcc ctgggggtcat agcttgggct 120
gttccttctc tgatacggga agagacccca atcagatttt tcaaattaa gccagtcctg 180
ggaaatctc 189
```

<210> 15

<211> 473

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 34, 59, 60, 134, 168, 311, 314, 344, 347, 354, 364, 391, 393, 401

<221> unsure

<222> 407, 413, 416, 426, 445, 446, 447, 453, 454, 459, 471

<223> a or g or c or t, unknown, or other

<220>

<221> misc\_feature

<223> Incyte clone 1391767F1

<400> 15

```
gaaaaaaagg aaatagcaat cttacgggaa agantcactg agctggaacg gaagctaann 60
ttcgaacagc agcgttctga tttgtgggaa agattgtatg ttgaggcaaa agatcaaaaat 120
ggaaaaaagc gaanagatgg aaaaaagaaa gggggcagag gaagccanag ggctaaaaat 180
aagtcaagg aaacattttt gggttcagtt aaggaaacat ttgatgccat gaagaattct 240
accaaggagt ttgtaaggca tcataaagag aaaattaagc aggctaaaga agctgtgaag 300
gaaaatctga naanattctc agattcagtt aaatccactt tccnggnact ttanagtacc 360
cccnagggta tctttgatga aaagggtaat nanagttttg ngctacnaaa gangcnagct 420
gaaaanccag gacagttttt agggnnntat tgnnatccnc agtataaggc ncc 473
```

<210> 16

<211> 529

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 119, 501

<223> a or g or c or t, unknown, or other

<220>

<221> misc\_feature

<223> Incyte clone 1477338F1

<400> 16  
 ccccagatgt ggccgaactc atccggacc ctaggaaat gcgttacatc cctttgaaag 60  
 tggccctgtt ctatctctta aatccttaca cgatcttggtc ttgtggtgcc aagtctacnt 120  
 gtgccatcaa caacaccctc attgctttct tcattttgac tacgataaaa ggcagtgcct 180  
 tcctcagtcg tatttttctt gccttagcga cataccagtc tctgtaccca ctcacctgt 240  
 ttgtcccagc actcctctat ctctccagc ggcagtacat acctgtgaaa atgaagagca 300  
 aagccttctg gatcttttct tgggagtatg ccatgatgta tgtgggaagc ctagtggtaa 360  
 tcatttgctt ctctctcttc cttctcagct cttgggattt catccccgca gtctatggct 420  
 ttatactttc tgttccagat ctcaactcaa acattgggtct tttctggtag ttctttgcag 480  
 agatgtttga gcacttcagc ntcttctttg tatgtgtgtt cagatcaac 529

<210> 17  
 <211> 581  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 372, 374, 445  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1520634F1

<400> 17  
 gccatcccc tgccctcagc ctctggcatt ttcctccggt gagaccatgg agggccctcc 60  
 ccgtcggact tgccgctccc cagaacctgg accttctctc tccatcggat ctccccaggc 120  
 ttcattctct ccaaggccca accactacct gcttattgac actcaggggtg tcccctacac 180  
 agtgctgggtg gacgaggagt cacagagggg gccagggggc agtgggggtc caggccagaa 240  
 aaagtgctac agctgccccg tgtgctcaag ggtcttcgag tacatgtcct accttcagcg 300  
 acacagcatc acccactcgg aggtaaagcc cttcagagtgt gacatctgtg ggaaggcatt 360  
 caagcgcgcc ancnaacttg cacggcacca ttccattcac ctggcgggtg gtgggcggcc 420  
 ccacggctgc ccgctctgcc ctcgncgttc cgggatgcgg gtgagctggc ccagcacagc 480  
 cgggtgact ctgggggaac cccgtttcag tgtcacactg cctcgccggt tatggagaga 540  
 acacactgca gaaacacacg ggtggaagca tccatgagcg g 581

<210> 18  
 <211> 637  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 462, 485, 510, 514, 550, 562, 602, 617, 622, 625, 629, 636  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1525569F6

<400> 18  
 cagtaatcag cccagtcctg cctttagacg acgccgtgct aggaagaaga ccgtttctgc 60

```

ttcagaatct gaagaccggc tagttgctga acaagaaact gaaccttcta aggagttgag 120
taaacgtcag ttcagtagtg gtctcaataa gtgtgttata cttgcttggg tgattgcaat 180
cagcatggga tttggccatt tctatggcac aattcagatt cagaagcgtc aacagttagt 240
cagaaagata catgaagatg aattgaatga tatgaaggat tatctttccc agtgtaaca 300
ggaacaagaa tcttttatag attataagtc attgaaagaa aatcttgcaa ggtgttgac 360
acttactgaa gcagagaaga tgtcctttga aactcagaaa acgaaccttg ctaccagaaa 420
atcagtatct aagagtatcc ttggagaagg aagaaaaagc cntatcctca ttaccagggg 480
agagntaaac aaacttaaga ggaccagttt gganattgga agataaaggg gacaagtact 540
gaattagttt aaggaaaatc cngaaacttt aagcagcctt tggaagaggg aaagccggaa 600
anacaccagc tttcctnagt cnaangggng accctnt 637

```

```

<210> 19
<211> 187
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> unsure
<222> 13, 19, 21
<223> a or g or c or t, unknown, or other

```

```

<220>
<221> misc_feature
<223> Incyte clone 1554775H1

```

```

<400> 19
gggcggagtt gtnggagtn nggaggaaga ggcggtaggg ggtacggggg ctggtcccag 60
aagatggcgg aggcggggga tttctggtag gtcctacttt aggacaagat gtggtaccgt 120
tgaagcgtca gtctttgatt cacagacagt tgagcttttc agctgggaag cctttccatt 180
ttttttt 187

```

```

<210> 20
<211> 499
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> unsure
<222> 406, 435
<223> a or g or c or t, unknown, or other

```

```

<220>
<221> misc_feature
<223> Incyte clone 1596581F6

```

```

<400> 20
aaaaagcaga aactcctcct agaactggac cagtatgcc cagatgtggc cgaactcacc 60
cggaccoccta tggaaatgcg ttacatccct ttgaaagtgg ccctgttcta tctcttaaatt 120
ccttacacga ttttgtcttg tgttgccaag tctacctgtg ccatcaacaa caccctcatt 180
gctttcttca ttttgactac gataaaaggc agtgccttcc tcagtgtctat ttttcttggc 240
ttagcgacat accagtctct gtaccactc acctgtttg tcccaggact cctctatctc 300

```

```

ctccagcggc agtacatacc tgtgaaaatg aagagcaaag ctttctggat cttttcttgg 360
gagtatgcca tgatgtatgt gggaaaccta gtggtaatca tttgcntctc cttcttcett 420
ctcagctctt ggganttcac ccccgcagtc taatggctta tactttctgt tccagatctc 480
atccaaacat tgggtcttt                                     499

```

<210> 21

<211> 287

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 122, 144, 266, 273

<223> a or g or c or t, unknown, or other

<220>

<221> misc\_feature

<223> Incyte clone 1596581T1

<400> 21

```

ggcttggccc agcttctggc cccacagccc cctgaggtcc atgcagccct gtgccagcca 60
ggcctacttg agcagcagca tggcctctgt gccatccttg gcggtcaagt agaggccatg 120
tntgaggtag tactcccgcc gcangaaggc atagaagtaa tcagagatga gcaggatctg 180
cccaacgttg aaggctcagtg tgatggcata aaagaaatta gagttggcac ttctgcata 240
aatccagagg tgccacagga caggnagaa cangggacag acgattt                                     287

```

<210> 22

<211> 579

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 22, 25, 32, 106, 123, 126, 135, 208, 216, 219, 234, 236, 263, 271

<221> unsure

<222> 282, 287, 292, 358, 360, 363, 365, 379, 412, 441, 452, 459, 483

<221> unsure

<222> 485, 499, 500

<223> a or g or c or t, unknown, or other

<220>

<221> misc\_feature

<223> Incyte clone 162871X4

<400> 22

```

ctaaagaaga gcggtagggg gncnnggggc tngtcccaga aagtatggcg gaggcggggg 60
atctctggta ggtcctactt taggacaaga tgtggtaccg ttgaancgct agtctttgat 120
tcncanacag ttganctttt cagctgggaa gcctttccat tttttttttt aacggctttc 180
tgaacctatg aaacctatgc aaaagganaa acaaantcnc ctgggcccac aaantntggc 240
ccatatattt catctgtcac tanccaaatt ntgaacttga tnattcnagg antattgcta 300
ttttttattg gagtatttct tgcattagtg ttaaatttac ttcaaattca aaaaaatntn 360
acnncntttc cacctgatnt gattgcaagc atcttttctt ctgcatgctg tnattggggt 420
attatacccc tgcattaaca nacatctagg anaaccacnt aaatttaaaa aaaagtggtc 480

```

cantntaatg cgggtgtgtnn cagtctttgt tggataaat catgccagtg ctaaagtgga 540  
 ttctgataac aacatacagt tgtctctcac actggcgca 579

<210> 23  
 <211> 250  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 8, 17, 24, 27, 33, 36, 43, 246  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 162871X92

<400> 23  
 ggaaaggnc aaggaanggg gtanggncgg tgntcnaaga aantggcgga ggcgggggat 60  
 ttctgctgtg attgggttat tataccoctg cattgacaga catctaggag aaccacataa 120  
 atttaaaaga gagcgggtcca gtgtaatgcy gtgtgtagca gtctttgttg gtataaatca 180  
 tgccagtgct aaagtggatt tcgataacaa catacagttg tctctcacac tggetgcact 240  
 atcttnaaaa 250

<210> 24  
 <211> 250  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 8  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1658067H1

<400> 24  
 cgacagtngg ggacgtggcg ctctacatgg cttctctccc cgtgtggaac catctctaca 60  
 gattcctgag aaacatcttt gtctctcacct gcatcatcat cgtctgttcc ctgctcttcc 120  
 ctgtcctgtg gcacctctgg atttatgcag gaagtgccaa ctotaatttc ttttatgcca 180  
 tcacactgac cttcaacggt gggcagatcc tgetcatctc tgattacttc tatgccttcc 240  
 tgcggcggga 250

<210> 25  
 <211> 736  
 <212> DNA  
 <213> Homo sapiens

<220>

<221> unsure  
 <222> 419, 435, 453, 462, 463, 471, 476, 513, 516, 563, 585, 586, 597  
 <221> unsure  
 <222> 611, 618, 652, 661, 680, 684, 685, 692, 693, 701, 714, 725, 731  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1706512F6

<400> 25  
 atcagaagct cttcactgac tttgttaatg atgttaaaga ttatcctaga aacatgaagg 60  
 aatatgaagt agataatgat ggagtatttg agaagttgga tgaatatata tatagacact 120  
 tctttgtgca cactttttcc cctccatag gaccagggtc ggtttacata aaaccgtgct 180  
 attacagtag tttgtaacat ttgtagattg gatagcattt ttatgatttg atgagtttct 240  
 tgtaaggtta ccgtttctaa gagttgtgct ttatgggcac tgagagaatt ccagaataaa 300  
 ttgaaagatg ggagtcctaa aaatttaatt agccgggtac caaatgggga cttttccat 360  
 tagtaacggt gattccacct ttggaccttt gaggccaaat gggtttaaat ttttttaanc 420  
 ccttaaaaaa atccnggttt aaaggaatta ttnttaaaga annccccacc nttttngggc 480  
 ccaaggtttt ggttttccct ttttccattt aanaanggtt ttaataatgg aaaaaaggat 540  
 tccacccttt aaaggtggga aantttaatt ttttccccct taaannccct ttttaanggg 600  
 aatttaaaatt nccccctnct gggaaagcca agggaatgga ggcccccccc cnaattttta 660  
 nccccggaag gtccggaagn ggcnnccat annaataatt nccaaagggtc cccncccaat 720  
 tttcnctgg ncccat 736

<210> 26  
 <211> 611  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 213, 223, 369, 406, 423, 469, 475, 490, 494, 498, 524, 548, 570  
 <221> unsure  
 <222> 574, 582, 584, 594, 597, 605, 607  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1722946F6

<400> 26  
 attggcgccc gagctgtgac cgccgccact ggggcagcca gcacaatcgg gcgaggtgg 60  
 cgctgccct tcagacctga aagatgtctg aaaattccag tgacagtgat tcatcttgty 120  
 gttggactgt catcagtcac gaggggtcag atatagaaat gttgaattct gtgaccccc 180  
 ctgacagctg tgagcccgcc ccagaatggt canctttaga gcnagaggag cttcaagcat 240  
 tgcagataga gcaaggagaa tgcagccaaa atggcacagt gcttatggaa gaaactgctt 300  
 atccagcttt ggaggaaacc agctcaacaa ttgaggcaga ggaacaaaag atacccgaag 360  
 acagtatcna tattggaact gccagtgggtg attctgatat tgttanccct tgagccacta 420  
 agnttagaag gaattgggga tccaagaagt tgtcattggt gaagaaagnc caagntccgg 480  
 agacttttan catnggntc ttcctctagc agccagtata cttntctggt cagcccagaa 540  
 aactggantt tcatcttcag cctaatgacn gtgnaatcaa gntngtgatg gaanccngtt 600  
 attcngnccc c 611

<210> 27  
 <211> 592  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 94, 104, 149, 167, 215, 226, 232, 275, 298, 301, 312, 333, 362  
 <221> unsure  
 <222> 364, 367, 376, 391, 392, 395, 412, 415, 419, 429, 435, 443, 449  
 <221> unsure  
 <222> 452, 462, 463, 464, 466, 467, 468, 470, 476, 485, 489, 492, 502  
 <221> unsure  
 <222> 514, 529, 533, 541, 550, 557, 558, 567, 572, 574, 577, 580  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 1853196F6

<400> 27  
 ctttcagaaa ggcttgttct ggtgtatttg attgtgctca acaagagtcc atgagccttt 60  
 ttaacacagt ggtgaatcct ataaggatgg atgnatntag acanataatt caaagggtaca 120  
 tgtaaaga actggatact ttttgtcant ggaacgaact tgatcanttc atcaataagt 180  
 ttttctaaa cgggtgtcttt atacatgatac agaancctctt cactgncttt gntaatgatg 240  
 ttaaagatta tcttagaaac atgaaggata tgaantagat aatgatggag tatttgcnaa 300  
 nttggatgga tntatatata gacacttctt tgntcacact ttttcccctc catatgggcc 360  
 cngntcngtt tacatnaaac cgtgtcttac nntantttgt aacatttcta gntgnatanc 420  
 atttttaant ttgangagtt tcntgtaang tnacggttcc annngnnntn ctttanagcc 480  
 accanagana antcggataa antgaaagta gggntccaaa attattaant gtnccaatag 540  
 nactttcctn ataaagnngt caccttngct tnancnntn ggtttaattt tt 592

<210> 28  
 <211> 447  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte clone 2238411F6

<400> 28  
 tttgggcacc agcctctgag ggcctcaaac caggccctga ggatgggccg ggcaaggagg 60  
 aagctccgga gctggacgag gccgaattgg actacctcat ggatgtgctg gtgggacac 120  
 aggcactgga gcgaccgocg gggccagggc gctgagccct cgtgctggaa tggttgtctg 180  
 gtatctgaac tgagcctgct ggctggacca actgtcctcg aaaagacaca gctggcttcc 240  
 ctagtacaga gaacagggct tgggacctt tggagagaca gaatctagtc ctgggcaact 300  
 tcacatccgt cctcctgtct cagggctggc agggggagcc tggattacc ccctagtgat 360  
 ggaatgacag ggtctggtgg ggactgaatt ccctggccct ggggtcatag cttgggctgt 420  
 tccttctctg atacgggaag agacccc 447

<210> 29  
 <211> 247

<212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 234  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 2312928H1

<400> 29  
 tgctgggtggg ggctgtgaca gtgcggggcgg ccttggtccg ctccagtctg gccgagttca 60  
 tttccgagcg ggtggaggtg gtgtccccac tgagctcttg gaagagagtg gttgaaggcc 120  
 tttcactggt ggacttggga gtatctccgt attctggagc agtatttcat gaaactccat 180  
 taataatata cctctttcat ttcttaattg actatgctga attgggtgtt atgntaactg 240  
 atgcact 247

<210> 30  
 <211> 190  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 162, 163  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte clone 3015795H1

<400> 30  
 acttcacatc cgtcctcctg tctcagggct ggcaggggga gcctggaatt accccctagt 60  
 gatggaatga caggtctctg tggggactga attccctggc cctgggggtca tagcttgggc 120  
 tgttccttct ctgatacggg aagagacccc aatcagattt tnnaaattaa agccagtcct 180  
 gggaaatctc 190

<210> 31  
 <211> 253  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> 121  
 <223> a or g or c or t, unknown, or other

<220>  
 <221> misc\_feature

<223> Incyte clone 3231214H1

<400> 31

```
gtttcagatc aacgtctttct tctacaccat ccccttagcc ataaagctaa aggagcacc 60
catcttcttc atgtttatcc agatcgctgt catcgccatc ttttaagtcct acccgacagt 120
nggggacgtg gcgctctaca tggcettctt ccccggtgtgg aaccatctct acagattcct 180
gagaaacatc tttgtcctca cctgcatcat catcgctctgt tccctggctc tccctgtcc 240
tgtggcacct ctg 253
```

<210> 32

<211> 273

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 88

<223> a or g or c or t, unknown, or other

<220>

<221> misc\_feature

<223> Incyte clone 3985439H1

<400> 32

```
gtcttccttg cgtgtgogtg cacgttgggt gctgggggggt ggagaccgga tctatcctcg 60
cttgggtact ttcctctcgg tgtgtgtntc tggccgggagc cgtttcgcga cggcccgggc 120
gccccgcccc aaccttcctt ccctagacc tcttctctcc ctteggcttc tctctttcgg 180
ccggcgccgc cagttcctgg ggcacacca gaggtcccct tctcgccgcc gcctgcaact 240
gcgagggtag cccggggccg cttggagtgc ccc 273
```

<210> 33

<211> 618

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 190, 336, 351, 413, 420, 423, 432, 441, 449, 454, 462, 510, 520

<221> unsure

<222> 524, 530, 552, 555, 557, 560, 561, 569, 574, 584, 585, 594, 596

<221> unsure

<222> 611, 614

<223> a or g or c or t, unknown, or other

<220>

<221> misc\_feature

<223> Incyte clone 403002R6

<400> 33

```
tgctggtgga cgaggagtca cagagggagc cagggggccag tggggctcca ggccagaaaa 60
agtgctacag ctgccccgtg tgctcaaggg tcttcgagta catgtcctac cttcagcgac 120
```

```

acagcatcac ccaactcggag gtaaagccct tcgagtgtga catctgtggg aaggcattca 180
agcgcgccan ccacttggca cggcaccatt ccattcacct ggcgggtggg gggcggcccc 240
acggctgccc gctctgccct cgccgcttcc gggatgcggg tgagtggccc aagcacagcc 300
gggtgcactc tggggaacgc cegtctcagt gtcaanactg ccttcgccgg ntttaatgga 360
gcagaacaca attgcagaaa acaacaccgc ggttggaaag catcccattg aanccggggg 420
ttncggggtt tnccccaagg ntaccaaang gaantttttc anaggggaac ccttgaaatt 480
ccctgttcca aaaaaacctt ggttaaaan ccctaaaggn tggnttttn aggggccttg 540
gaaaaacagg ancananggn nagcgggant tttnaaagg aaannccctt gccnanaagg 600
gggaatcccg naantaat 618

```

```

<210> 34
<211> 297
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte clone 510407R6

```

```

<400> 34
tgagtaatct tcaggtcctc cgtgttctgg agctgagatg ggaatgagcc cctacacaga 60
atggagtccct ctagcctaaa gatatcagct gttccatggc agagccttga ctggatggag 120
gtggggagtg tgggtgtgtaa agtctctggc ctcataaaaag gtggctgtgg gtctgcagga 180
atctgcgcca tcttctctggg gcttctgcgc tgttggtggg gaagggaccc cagtctgcc 240
ttccaccccc caaccaggcc tgagactgat caaacaataa acacgtttcc cactctg 297

```

```

<210> 35
<211> 239
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> unsure
<222> 91
<223> a or g or c or t, unknown, or other

```

```

<220>
<221> misc_feature
<223> Incyte clone 3590729H1

```

```

<400> 35
ggcgagtgct tgggcagaag aggttcgagt ccagggtcac aagtctctgg taccaaaagg 60
gacccatggc tgactgacag caaggcctat ngggaagaac tgggagctcc ccaacttggg 120
ccccacctt gtggctctgc acaccaagga gcccctccc agacaggaag gagaagaggc 180
aggtgagcag ggcttgtag attgtggcta cttataaat gttttttggt atgaagtct 239

```